STOCK TITAN

PetVivo has $16.3K cash; going-concern doubt remains

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

PetVivo Holdings, Inc. reported third-quarter revenue of $212,806, versus $303,284 a year earlier; six-month revenue was $550,377 versus $600,784. Net loss was $1,946,531 for the quarter and $3,560,419 for six months, compared with revised 2025 losses of $2,244,550 and $4,555,587. Six-month operating cash use was $1,912,820.

PetVivo terminated its VetStem license on July 24, 2026, paid $75,000, returned inventory with a $120,046 net carrying value and recorded a $237,530 loss; VetStem forgave $282,516 in payables, royalties and a milestone payment. At September 30, cash was $16,287, the working-capital deficit was $1,559,817, and current non-convertible notes payable including interest were $1,296,850. It issued another $360,000 of stockholder notes after quarter-end.

Management said substantial doubt about continuing as a going concern is not alleviated. Its $2 million private equity offering, initiated in late October, had no signed subscriptions or proceeds as of the report date. The company revised 2025 comparisons to remove a $763,259 accounting error, with no effect on cash, total assets, liabilities, equity or operating cash flow.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 3 points

How the balance works

Positive

  • Moderate pointSix-month net loss narrowed to $3,560,419 from $4,555,587.
  • Moderate pointSix-month operating cash use narrowed to $1,912,820 from $3,828,209.

Negative

  • Major pointSubstantial doubt about continuing as a going concern remains unalleviated.
  • Moderate pointQuarterly revenue fell to $212,806 from $303,284.
  • Minor pointSix-month revenue fell to $550,377 from $600,784.

Filing Explained

Series B preferred dividends are paid in common shares, and preferred holders rank ahead of common stock in liquidation.

In its unaudited quarterly report, PetVivo Holdings reports 2,279,726 common shares issued during the six months ended September 30, 2026; common shares outstanding rose from 35,849,919 on March 31, 2026 to 38,129,645 on September 30, 2026, and were 38,536,433 on November 16, 2026. These completed issuances increase the total share count and reduce existing holders’ percentage ownership, absent offsetting changes.

At September 30, 2026, 5,000,000 Series B preferred shares were outstanding; their terms provide an annual dividend equal to 10% of the amount paid, paid quarterly in common shares, and give preferred holders priority over common stock in liquidation up to the original issue price.

In a separate June placement, an investor bought 187,500 shares for $150,000; the remaining $1.35 million is an optional purchase, not an obligation, and was extended to December 15, 2026. No additional proceeds from that option had been received by the filing date.

Three-month revenue $212,806 Three months ended September 30, 2026; $303,284 in the 2025 comparison.
Six-month revenue $550,377 Six months ended September 30, 2026; $600,784 in the 2025 comparison.
Six-month net loss $3,560,419 Six months ended September 30, 2026; revised 2025 comparison was $4,555,587.
Net cash used in operating activities $1,912,820 used Six months ended September 30, 2026; $3,828,209 used in the revised 2025 comparison.
Cash $16,287 As of September 30, 2026.
Working-capital deficit $1,559,817 As of September 30, 2026.
Current non-convertible notes payable, including accrued interest $1,296,850 As of September 30, 2026.
Loss on termination of license agreement $237,530 Recognized for the three and six months ended September 30, 2026.
beneficial conversion feature financial
"remove the beneficial conversion feature and the related amortization of the debt discount"
debt discount financial
"removing the beneficial conversion feature and the related amortization of the debt discount"
The shortfall between a debt instrument’s face (par) value and the lower price at which it is sold or traded. When debt is issued or traded at a discount, the buyer pays less than the amount that will be repaid at maturity; that discount implies a higher effective yield to the buyer than the stated coupon and, for accounting, is amortized over the life of the debt (or recorded as a loss if the discount reflects a negotiated reduction in repayment).
working capital deficit financial
"The Company had a working capital deficit of $1,559,817"
A working capital deficit occurs when a company's short-term obligations—like bills, supplier payments and near-term debt—are larger than its readily available short-term resources such as cash, money expected from customers, and inventory that can be sold. Like a household whose monthly bills exceed its checking account, it signals potential difficulty paying immediate expenses, which matters to investors because it raises the chance the company will need outside financing or cut operations, affecting risk and value.
going concern financial
"substantial doubt about the Company’s ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
anti-dilutive financial
"the inclusion of all potentially dilutive securities would be anti-dilutive"
A claim, security feature, or action described as anti-dilutive prevents or does not cause a reduction in existing shareholders’ per-share values when additional shares could be issued. For example, certain convertible securities or corporate actions are treated as anti-dilutive for earnings-per-share calculations if including them would raise EPS rather than lower it; investors watch this because it affects reported per-share metrics, ownership percentages, and valuation comparisons, like keeping pie slices the same size instead of making them smaller.
derivative liabilities financial
"The following table summarizes activity in the Company’s derivative liabilities"
Derivative liabilities are obligations a company records when it owes money under financial contracts whose value depends on something else, like interest rates, stock prices, or currencies. Think of them as bets or insurance policies that can create future cash payments; they matter to investors because they can cause sudden changes in a company’s reported debt, profits and cash flow and reveal exposure to market risks that could affect valuation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was PETV's revenue in the latest quarter?

PETV reported $212,806 in revenue for the three months ended September 30, 2026. Revenue for the same three months in 2025 was $303,284. For the six months ended September 30, 2026, revenue was $550,377, compared with $600,784 in 2025.

How did PETV revise its 2025 financial statements?

PetVivo removed a $763,259 beneficial conversion feature and related debt-discount amortization from its revised 2025 comparative financial statements. The correction reduced reported interest expense and net loss for the six months ended September 30, 2025 by $763,259 and did not affect cash, total assets, total liabilities, total stockholders’ equity or net cash used in operating activities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false Q2 2027 --03-31 0001512922 0001512922 2026-04-01 2026-09-30 0001512922 2026-11-16 0001512922 2026-09-30 0001512922 2026-03-31 0001512922 us-gaap:RelatedPartyMember 2026-09-30 0001512922 us-gaap:RelatedPartyMember 2026-03-31 0001512922 us-gaap:PreferredClassBMember 2026-09-30 0001512922 us-gaap:PreferredClassBMember 2026-03-31 0001512922 us-gaap:SeriesBPreferredStockMember 2026-09-30 0001512922 us-gaap:SeriesBPreferredStockMember 2026-03-31 0001512922 2026-07-01 2026-09-30 0001512922 2025-07-01 2025-09-30 0001512922 2025-04-01 2025-09-30 0001512922 us-gaap:CommonStockMember 2026-03-31 0001512922 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-03-31 0001512922 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2026-03-31 0001512922 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001512922 PETV:CommonStockToBeIssuedMember 2026-03-31 0001512922 us-gaap:RetainedEarningsMember 2026-03-31 0001512922 us-gaap:CommonStockMember 2026-06-30 0001512922 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-06-30 0001512922 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2026-06-30 0001512922 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001512922 PETV:CommonStockToBeIssuedMember 2026-06-30 0001512922 us-gaap:RetainedEarningsMember 2026-06-30 0001512922 2026-06-30 0001512922 us-gaap:CommonStockMember 2025-03-31 0001512922 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-03-31 0001512922 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2025-03-31 0001512922 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001512922 us-gaap:RetainedEarningsMember 2025-03-31 0001512922 2025-03-31 0001512922 us-gaap:CommonStockMember 2025-06-30 0001512922 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-06-30 0001512922 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2025-06-30 0001512922 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001512922 us-gaap:RetainedEarningsMember 2025-06-30 0001512922 2025-06-30 0001512922 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001512922 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-04-01 2026-06-30 0001512922 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2026-04-01 2026-06-30 0001512922 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001512922 PETV:CommonStockToBeIssuedMember 2026-04-01 2026-06-30 0001512922 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001512922 2026-04-01 2026-06-30 0001512922 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001512922 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-07-01 2026-09-30 0001512922 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2026-07-01 2026-09-30 0001512922 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001512922 PETV:CommonStockToBeIssuedMember 2026-07-01 2026-09-30 0001512922 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001512922 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001512922 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-04-01 2025-06-30 0001512922 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2025-04-01 2025-06-30 0001512922 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001512922 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001512922 2025-04-01 2025-06-30 0001512922 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001512922 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-07-01 2025-09-30 0001512922 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2025-07-01 2025-09-30 0001512922 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001512922 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001512922 us-gaap:CommonStockMember 2026-09-30 0001512922 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-09-30 0001512922 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2026-09-30 0001512922 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001512922 PETV:CommonStockToBeIssuedMember 2026-09-30 0001512922 us-gaap:RetainedEarningsMember 2026-09-30 0001512922 us-gaap:CommonStockMember 2025-09-30 0001512922 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-09-30 0001512922 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2025-09-30 0001512922 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001512922 us-gaap:RetainedEarningsMember 2025-09-30 0001512922 2025-09-30 0001512922 PETV:ProductionAndComputerEquipmentAndFurnitureMember srt:MinimumMember 2026-09-30 0001512922 PETV:ProductionAndComputerEquipmentAndFurnitureMember srt:MaximumMember 2026-09-30 0001512922 PETV:PatentsAndTrademarksMember 2026-09-30 0001512922 us-gaap:PatentsMember 2026-09-30 0001512922 PETV:OptionsAndWarrantsMember 2026-04-01 2026-09-30 0001512922 PETV:OptionsAndWarrantsMember 2025-04-01 2025-09-30 0001512922 PETV:ConversionOfStockMember 2026-04-01 2026-09-30 0001512922 PETV:ConversionOfStockMember 2025-04-01 2025-09-30 0001512922 us-gaap:RestrictedStockUnitsRSUMember 2026-04-01 2026-09-30 0001512922 us-gaap:RestrictedStockUnitsRSUMember 2025-04-01 2025-09-30 0001512922 PETV:DistributionAgreementMember 2025-02-28 0001512922 PETV:DistributionAgreementMember 2025-02-01 2025-02-28 0001512922 PETV:DistributionAgreementMember 2026-04-01 2026-09-30 0001512922 PETV:VedcoIncMember 2026-07-01 2026-09-30 0001512922 PETV:VedcoIncMember 2025-07-01 2025-09-30 0001512922 PETV:ClipperDistributingLLCMember 2026-07-01 2026-09-30 0001512922 PETV:ClipperDistributingLLCMember 2025-07-01 2025-09-30 0001512922 PETV:SpryngProductsMember 2026-07-01 2026-09-30 0001512922 PETV:PrecisePRPProductsMember 2026-07-01 2026-09-30 0001512922 PETV:DistributionAgreementMember 2026-07-01 2026-09-30 0001512922 PETV:SpryngProductsMember 2025-07-01 2025-09-30 0001512922 PETV:PrecisePRPProductsMember 2025-07-01 2025-09-30 0001512922 PETV:VedcoIncMember 2026-04-01 2026-09-30 0001512922 PETV:VedcoIncMember 2025-04-01 2025-09-30 0001512922 PETV:ClipperDistributingLLCMember 2026-04-01 2026-09-30 0001512922 PETV:ClipperDistributingLLCMember 2025-04-01 2025-09-30 0001512922 PETV:SpryngProductsMember 2026-04-01 2026-09-30 0001512922 PETV:PrecisePRPProductsMember 2026-04-01 2026-09-30 0001512922 PETV:SpryngProductsMember 2025-04-01 2025-09-30 0001512922 PETV:PrecisePRPProductsMember 2025-04-01 2025-09-30 0001512922 PETV:VedcoIncMember 2026-09-30 0001512922 PETV:VedcoIncMember 2026-03-31 0001512922 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-03-31 0001512922 srt:ScenarioPreviouslyReportedMember 2026-03-31 0001512922 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2025-04-01 2026-03-31 0001512922 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2025-09-30 0001512922 srt:ScenarioPreviouslyReportedMember 2025-09-30 0001512922 2025-09-01 2025-09-30 0001512922 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2025-04-01 2025-09-30 0001512922 srt:ScenarioPreviouslyReportedMember 2025-04-01 2025-09-30 0001512922 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2025-04-01 2025-09-30 0001512922 srt:ScenarioPreviouslyReportedMember 2025-07-01 2025-09-30 0001512922 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2025-07-01 2025-09-30 0001512922 PETV:PrecisePRPMember 2026-09-30 0001512922 PETV:PrecisePRPMember 2026-04-01 2026-09-30 0001512922 PETV:PrecisePRPMember 2026-07-24 2026-07-24 0001512922 us-gaap:LeaseholdImprovementsMember 2026-09-30 0001512922 us-gaap:LeaseholdImprovementsMember 2026-03-31 0001512922 us-gaap:EquipmentMember 2026-09-30 0001512922 us-gaap:EquipmentMember 2026-03-31 0001512922 PETV:ResearchAndDevelopmentEquipmentMember 2026-09-30 0001512922 PETV:ResearchAndDevelopmentEquipmentMember 2026-03-31 0001512922 PETV:ComputerEquipmentAndFurnitureMember 2026-09-30 0001512922 PETV:ComputerEquipmentAndFurnitureMember 2026-03-31 0001512922 us-gaap:LicensingAgreementsMember 2025-02-01 2026-02-28 0001512922 us-gaap:LicensingAgreementsMember 2025-02-28 0001512922 us-gaap:LicensingAgreementsMember 2025-02-01 2025-02-28 0001512922 2025-08-01 2025-08-31 0001512922 2025-11-01 2025-11-30 0001512922 us-gaap:LicensingAgreementsMember 2025-08-01 2025-11-30 0001512922 srt:MinimumMember us-gaap:LicensingAgreementsMember 2025-02-01 2025-02-28 0001512922 srt:MaximumMember us-gaap:LicensingAgreementsMember 2025-02-01 2025-02-28 0001512922 2025-02-28 0001512922 us-gaap:MeasurementInputExpectedDividendPaymentMember 2025-02-28 0001512922 us-gaap:MeasurementInputPriceVolatilityMember 2026-02-28 0001512922 us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-02-28 0001512922 us-gaap:MeasurementInputExpectedTermMember 2025-02-28 0001512922 2025-04-01 2026-03-31 0001512922 PETV:VetStemLicenseMember 2026-07-01 2026-09-30 0001512922 PETV:VetStemLicenseMember 2025-07-01 2025-09-30 0001512922 PETV:VetStemLicenseMember 2026-04-01 2026-09-30 0001512922 PETV:VetStemLicenseMember 2025-04-01 2025-09-30 0001512922 PETV:VetStemLicenseMember 2026-07-01 2026-07-24 0001512922 PETV:PrecisePRPMember 2026-07-24 0001512922 PETV:VetStemLicenseMember 2026-07-24 0001512922 us-gaap:LicensingAgreementsMember 2025-09-01 2025-09-30 0001512922 us-gaap:CommonStockMember us-gaap:LicensingAgreementsMember 2025-09-01 2025-09-30 0001512922 us-gaap:LicensingAgreementsMember 2025-09-30 0001512922 srt:MinimumMember us-gaap:LicensingAgreementsMember 2025-09-01 2025-09-30 0001512922 srt:MaximumMember us-gaap:LicensingAgreementsMember 2025-09-01 2025-09-30 0001512922 us-gaap:LicensingAgreementsMember 2026-07-01 2026-09-30 0001512922 us-gaap:LicensingAgreementsMember 2026-04-01 2026-09-30 0001512922 us-gaap:LicensingAgreementsMember 2025-07-01 2025-09-30 0001512922 us-gaap:LicensingAgreementsMember 2025-04-01 2025-09-30 0001512922 PETV:DigitalLandiaHoldingCorpMember 2026-07-01 2026-09-30 0001512922 PETV:DigitalLandiaHoldingCorpMember 2025-07-01 2025-09-30 0001512922 PETV:DigitalLandiaHoldingCorpMember 2026-04-01 2026-09-30 0001512922 PETV:DigitalLandiaHoldingCorpMember 2025-04-01 2025-09-30 0001512922 PETV:TwoSeperatePromissoryNotesMember 2026-02-28 0001512922 PETV:TwoSeperatePromissoryNotesMember 2026-03-31 0001512922 PETV:FirstPromissoryNotesMember 2026-02-26 0001512922 PETV:FirstPromissoryNotesMember 2026-02-26 2026-02-26 0001512922 PETV:SecondPromissoryNotesMember 2026-03-11 0001512922 PETV:SecondPromissoryNotesMember 2026-03-11 2026-03-11 0001512922 PETV:TwoSeperatePromissoryNotesMember 2026-02-01 2026-02-28 0001512922 PETV:TwoSeperatePromissoryNotesMember 2026-03-01 2026-03-31 0001512922 PETV:AnotherPromissoryNotesMember 2026-06-22 0001512922 PETV:AnotherPromissoryNotesMember 2026-06-22 2026-06-22 0001512922 PETV:TwoSeperatePromissoryNotesMember 2026-07-31 0001512922 PETV:FirstPromissoryNotesMember 2026-07-09 0001512922 PETV:FirstPromissoryNotesMember 2026-07-09 2026-07-09 0001512922 PETV:SecondPromissoryNotesMember 2026-07-27 0001512922 PETV:SecondPromissoryNotesMember 2026-07-27 2026-07-27 0001512922 PETV:TwoSeperatePromissoryNotesMember 2026-07-01 2026-07-31 0001512922 PETV:ThreeSeperatePromissoryNotesMember 2026-08-31 0001512922 PETV:FirstPromissoryNotesMember 2026-08-10 0001512922 PETV:FirstPromissoryNotesMember 2026-08-10 2026-08-10 0001512922 PETV:SecondPromissoryNotesMember 2026-08-10 0001512922 PETV:SecondPromissoryNotesMember 2026-08-10 2026-08-10 0001512922 PETV:ThirdPromissoryNotesMember 2026-08-26 0001512922 PETV:ThirdPromissoryNotesMember 2026-08-26 2026-08-26 0001512922 PETV:ThreeSeperatePromissoryNotesMember 2026-08-01 2026-08-31 0001512922 PETV:ThreeSeperatePromissoryNotesMember 2026-09-30 0001512922 PETV:FirstPromissoryNotesMember 2026-09-11 0001512922 PETV:FirstPromissoryNotesMember 2026-09-11 2026-09-11 0001512922 PETV:SecondPromissoryNotesMember 2026-09-22 0001512922 PETV:SecondPromissoryNotesMember 2026-09-22 2026-09-22 0001512922 PETV:ThirdPromissoryNotesMember 2026-09-23 0001512922 PETV:ThirdPromissoryNotesMember 2026-09-23 2026-09-23 0001512922 PETV:ThreeSeperatePromissoryNotesMember 2026-09-01 2026-09-30 0001512922 us-gaap:ConvertibleDebtMember 2024-03-08 0001512922 us-gaap:ConvertibleDebtMember 2024-04-10 0001512922 us-gaap:ConvertibleDebtMember 2024-04-29 2024-04-29 0001512922 us-gaap:ConvertibleDebtMember 2024-04-29 0001512922 us-gaap:CommonStockMember 2024-04-29 2024-04-29 0001512922 us-gaap:ConvertibleDebtMember 2025-03-31 0001512922 us-gaap:ConvertibleDebtMember 2025-06-10 0001512922 us-gaap:MeasurementInputExpectedDividendPaymentMember 2025-03-31 0001512922 us-gaap:MeasurementInputPriceVolatilityMember 2025-03-31 0001512922 us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-03-31 0001512922 us-gaap:MeasurementInputExpectedTermMember 2025-03-31 0001512922 us-gaap:ConvertibleDebtMember 2025-09-30 2025-09-30 0001512922 PETV:ConvertiblePromissoryNoteMember 2025-09-30 2025-09-30 0001512922 PETV:ConvertiblePromissoryNoteMember 2025-09-30 0001512922 PETV:ConvertibleNotesMember 2025-09-30 2025-09-30 0001512922 PETV:ConvertibleNotesMember 2025-09-30 0001512922 PETV:ConvertibleNotesMember srt:MinimumMember 2025-09-30 0001512922 PETV:ConvertibleNotesMember srt:MaximumMember 2025-09-30 0001512922 us-gaap:ConvertibleNotesPayableMember 2026-09-30 0001512922 us-gaap:ConvertibleNotesPayableMember 2026-03-31 0001512922 PETV:ConvertiblePromissoryNoteMember 2026-07-01 2026-09-30 0001512922 PETV:ConvertiblePromissoryNoteMember 2025-07-01 2025-09-30 0001512922 PETV:ConvertiblePromissoryNoteMember 2026-04-01 2026-09-30 0001512922 PETV:ConvertiblePromissoryNoteMember 2025-04-01 2025-09-30 0001512922 2026-01-01 2026-09-30 0001512922 us-gaap:ConvertibleDebtMember 2025-02-14 0001512922 us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2025-02-14 0001512922 us-gaap:ConvertibleDebtMember us-gaap:WarrantMember us-gaap:MeasurementInputOfferedPriceMember 2025-02-14 0001512922 us-gaap:ConvertibleDebtMember us-gaap:WarrantMember us-gaap:MeasurementInputSharePriceMember 2025-02-14 0001512922 us-gaap:ConvertibleDebtMember us-gaap:WarrantMember us-gaap:MeasurementInputExpectedTermMember 2025-02-14 0001512922 us-gaap:ConvertibleDebtMember us-gaap:WarrantMember us-gaap:MeasurementInputOptionVolatilityMember 2025-02-14 0001512922 us-gaap:ConvertibleDebtMember us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-02-14 0001512922 us-gaap:ConvertibleDebtMember us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2025-02-14 0001512922 us-gaap:ConvertibleDebtMember 2025-04-01 2025-09-30 0001512922 us-gaap:ConvertibleDebtMember 2025-09-30 0001512922 us-gaap:ConvertibleDebtMember 2026-07-01 2026-09-30 0001512922 us-gaap:ConvertibleDebtMember 2025-07-01 2025-09-30 0001512922 us-gaap:ConvertibleDebtMember 2026-04-01 2026-09-30 0001512922 2025-06-30 2025-06-30 0001512922 us-gaap:MeasurementInputSharePriceMember 2025-02-14 0001512922 us-gaap:MeasurementInputSharePriceMember 2025-03-31 0001512922 us-gaap:MeasurementInputSharePriceMember 2025-06-30 0001512922 us-gaap:MeasurementInputConversionPriceMember 2025-02-14 0001512922 us-gaap:MeasurementInputConversionPriceMember 2025-03-31 0001512922 us-gaap:MeasurementInputConversionPriceMember 2025-06-30 0001512922 us-gaap:MeasurementInputExpectedTermMember 2025-02-14 0001512922 us-gaap:MeasurementInputExpectedTermMember 2025-06-30 0001512922 us-gaap:MeasurementInputPriceVolatilityMember 2025-02-14 0001512922 us-gaap:MeasurementInputPriceVolatilityMember 2025-06-30 0001512922 us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-02-14 0001512922 us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-06-30 0001512922 us-gaap:MeasurementInputExpectedDividendRateMember 2025-02-14 0001512922 us-gaap:MeasurementInputExpectedDividendRateMember 2025-03-31 0001512922 us-gaap:MeasurementInputExpectedDividendRateMember 2025-06-30 0001512922 2024-03-31 0001512922 2024-04-01 2025-03-31 0001512922 2025-07-01 2026-09-30 0001512922 PETV:ElevenUnsecuredNonconvertiblePromissoryNotesMember 2026-09-30 0001512922 PETV:ElevenUnsecuredNonconvertiblePromissoryNotesMember 2026-02-26 2026-09-30 0001512922 PETV:ElevenUnsecuredNonconvertiblePromissoryNotesMember srt:MinimumMember 2026-09-30 0001512922 PETV:ElevenUnsecuredNonconvertiblePromissoryNotesMember srt:MaximumMember 2026-09-30 0001512922 PETV:ElevenUnsecuredNonconvertiblePromissoryNotesMember 2026-03-31 0001512922 PETV:ElevenUnsecuredNonconvertiblePromissoryNotesMember 2026-07-01 2026-09-30 0001512922 PETV:ElevenUnsecuredNonconvertiblePromissoryNotesMember 2026-04-01 2026-09-30 0001512922 PETV:FourUnsecuredNonconvertiblePromissoryNotesMember us-gaap:SubsequentEventMember 2026-11-03 0001512922 PETV:FourUnsecuredNonconvertiblePromissoryNotesMember us-gaap:SubsequentEventMember 2026-10-13 2026-11-03 0001512922 PETV:MrHandleyAndDrPickettMember 2026-04-01 2026-09-30 0001512922 PETV:CEOAndCFOMember 2026-09-01 2026-09-30 0001512922 PETV:CEOAndCFOMember 2026-09-30 0001512922 PETV:DianeLevitanMember 2026-09-22 0001512922 PETV:DianeLevitanMember 2026-09-22 2026-09-22 0001512922 2017-05-31 0001512922 2017-05-01 2017-05-31 0001512922 PETV:ExtendedLeaseTermToTwoThousandTwentySixMember 2020-01-01 2020-01-31 0001512922 PETV:ExtendedLeaseTermToTwoThousandTwentySixMember 2020-01-31 0001512922 PETV:ExtendedLeaseTermToTwoThousandTwentySixMember 2026-04-01 2026-09-30 0001512922 PETV:ExtendedLeaseTermToTwoThousandTwentySixMember 2025-04-01 2026-03-31 0001512922 PETV:JanuaryTwoThousandTwentyTwoLeaseMember 2022-01-31 0001512922 PETV:JanuaryTwoThousandTwentyTwoLeaseMember 2022-01-01 2022-01-31 0001512922 PETV:JanuaryTwoThousandTwentyTwoLeaseMember 2026-04-01 2026-09-30 0001512922 PETV:JanuaryTwoThousandTwentyTwoLeaseMember 2025-04-01 2026-03-31 0001512922 PETV:JanuaryTenTwoThousandTwentyThreeLeaseMember 2023-01-10 0001512922 PETV:JanuaryTenTwoThousandTwentyThreeLeaseMember 2023-01-10 2023-01-10 0001512922 PETV:TenYearLeaseAgreementMember 2025-06-30 0001512922 PETV:TenYearLeaseAgreementMember PETV:UnrentedOfficeAreaMember 2026-09-30 0001512922 PETV:NovemberSevenTwoThousandTwentySixMember 2026-06-30 0001512922 PETV:ExtendedLeaseTermToTwoThousandTwentySixMember 2026-09-30 0001512922 us-gaap:SubsequentEventMember 2026-10-31 0001512922 us-gaap:SubsequentEventMember 2026-11-13 0001512922 us-gaap:SubsequentEventMember 2026-11-01 2026-11-13 0001512922 PETV:TwoThousandAndTwentyEquityIncentivePlanMember 2020-07-10 0001512922 PETV:AmendedPlanMember 2022-10-13 0001512922 PETV:AmendedPlanMember 2022-10-14 0001512922 PETV:AmendedPlanMember 2026-09-30 0001512922 us-gaap:PrivatePlacementMember us-gaap:RestrictedStockMember 2026-03-01 2026-03-31 0001512922 us-gaap:PrivatePlacementMember us-gaap:RestrictedStockMember 2026-03-31 0001512922 2026-04-20 2026-04-20 0001512922 us-gaap:PrivatePlacementMember us-gaap:RestrictedStockMember 2026-06-01 2026-06-30 0001512922 us-gaap:PrivatePlacementMember us-gaap:RestrictedStockMember 2026-06-30 0001512922 us-gaap:PrivatePlacementMember us-gaap:RestrictedStockMember us-gaap:InvestorMember 2026-06-01 2026-06-30 0001512922 us-gaap:PrivatePlacementMember us-gaap:InvestorMember 2026-06-01 2026-06-30 0001512922 us-gaap:PrivatePlacementMember PETV:CEOAndCFOMember us-gaap:RestrictedStockMember 2026-09-01 2026-09-30 0001512922 us-gaap:PrivatePlacementMember PETV:CEOAndCFOMember us-gaap:RestrictedStockMember 2026-09-30 0001512922 PETV:SubscriptionAgreementsMember us-gaap:SeriesBPreferredStockMember 2025-03-26 0001512922 PETV:SubscriptionAgreementsMember 2025-03-26 2025-03-26 0001512922 PETV:SubscriptionAgreementsMember us-gaap:InvestorMember 2025-03-26 2025-03-26 0001512922 2026-04-01 2026-04-30 0001512922 2026-06-01 2026-06-30 0001512922 2026-04-30 0001512922 PETV:ServiceProviderMember 2026-06-01 2026-06-30 0001512922 PETV:EmployeesMember 2026-04-01 2026-09-30 0001512922 us-gaap:SeriesBPreferredStockMember 2026-04-01 2026-04-30 0001512922 us-gaap:SeriesBPreferredStockMember 2026-04-30 2026-04-30 0001512922 srt:BoardOfDirectorsChairmanMember 2026-04-01 2026-04-30 0001512922 srt:BoardOfDirectorsChairmanMember 2026-07-01 2026-09-30 0001512922 2026-07-01 2026-07-31 0001512922 us-gaap:SeriesBPreferredStockMember 2026-07-01 2026-07-31 0001512922 srt:BoardOfDirectorsChairmanMember 2026-07-01 2026-07-31 0001512922 srt:BoardOfDirectorsChairmanMember 2026-09-01 2026-09-30 0001512922 srt:BoardOfDirectorsChairmanMember PETV:VWAPOneMember 2026-09-01 2026-09-30 0001512922 PETV:VWAPOneMember 2026-09-01 2026-09-30 0001512922 2026-09-01 2026-09-30 0001512922 us-gaap:EmployeeStockOptionMember 2026-04-01 2026-09-30 0001512922 us-gaap:EmployeeStockOptionMember 2026-07-01 2026-09-30 0001512922 us-gaap:EmployeeStockOptionMember 2025-07-01 2025-09-30 0001512922 us-gaap:EmployeeStockOptionMember 2025-04-01 2025-09-30 0001512922 PETV:ConsultingAgreementMember 2025-09-30 0001512922 PETV:ConsultingAgreementMember 2026-07-01 2026-09-30 0001512922 PETV:ConsultingAgreementMember 2026-04-01 2026-09-30 0001512922 PETV:ConsultingAgreementMember 2026-09-30 0001512922 PETV:ConsultingAgreementMember srt:MinimumMember 2026-04-01 2026-09-30 0001512922 PETV:ConsultingAgreementMember srt:MaximumMember 2026-04-01 2026-09-30 0001512922 us-gaap:WarrantMember 2026-09-30 0001512922 us-gaap:WarrantMember srt:MinimumMember 2026-09-30 0001512922 us-gaap:WarrantMember srt:MaximumMember 2026-09-30 0001512922 us-gaap:WarrantMember srt:MinimumMember 2026-03-31 0001512922 us-gaap:WarrantMember srt:MaximumMember 2026-03-31 0001512922 us-gaap:WarrantMember 2026-04-01 2026-09-30 0001512922 us-gaap:WarrantMember srt:MinimumMember 2025-04-01 2026-03-31 0001512922 us-gaap:WarrantMember srt:MaximumMember 2025-04-01 2026-03-31 0001512922 us-gaap:WarrantMember srt:MinimumMember 2026-04-01 2026-09-30 0001512922 us-gaap:WarrantMember srt:MaximumMember 2026-04-01 2026-09-30 0001512922 us-gaap:WarrantMember 2025-04-01 2026-03-31 0001512922 us-gaap:WarrantMember 2026-03-31 0001512922 PETV:SingleReportableSegmentMember 2026-04-01 2026-09-30 0001512922 us-gaap:OperatingSegmentsMember 2026-07-01 2026-09-30 0001512922 us-gaap:OperatingSegmentsMember 2025-07-01 2025-09-30 0001512922 us-gaap:OperatingSegmentsMember 2026-04-01 2026-09-30 0001512922 us-gaap:OperatingSegmentsMember 2025-04-01 2025-09-30 0001512922 PETV:StrategicAllianceAgreementMember PETV:DigitalLandiaCorpMember 2025-03-31 0001512922 PETV:RestrictedCommonStockMember PETV:StrategicAllianceAgreementMember 2025-03-01 2025-03-31 0001512922 PETV:DigitalLandiaCorpMember 2025-03-31 0001512922 PETV:StrategicAllianceAgreementMember 2025-03-01 2025-03-31 0001512922 PETV:DigitalLandiaHoldingCorpMember us-gaap:WarrantMember 2025-03-31 0001512922 PETV:DigitalLandiaHoldingCorpMember 2026-09-30 0001512922 PETV:DigitalLandiaHoldingCorpMember 2026-04-01 2026-09-30 0001512922 us-gaap:SubsequentEventMember us-gaap:SeriesBPreferredStockMember 2026-10-01 2026-10-31 0001512922 us-gaap:SubsequentEventMember 2026-10-06 0001512922 us-gaap:SubsequentEventMember PETV:TwoBoardMembersMember 2026-10-01 2026-10-31 0001512922 us-gaap:SubsequentEventMember 2026-10-13 2026-11-03 0001512922 us-gaap:SubsequentEventMember PETV:FiveBoardMembersMember us-gaap:RestrictedStockMember 2026-10-01 2026-10-31 0001512922 us-gaap:SubsequentEventMember PETV:EmployeesMember us-gaap:RestrictedStockMember 2026-10-12 2026-10-12 0001512922 us-gaap:SubsequentEventMember 2026-10-01 2026-10-31 0001512922 us-gaap:SubsequentEventMember 2026-10-29 0001512922 us-gaap:SubsequentEventMember 2026-10-29 2026-10-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:sqft PETV:Segment PETV:Token

 

 

 

U.S. SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

Mark One

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _______ to _______

 

Commission File No. 001-40715

 

PetVivo Holdings, Inc.

(Name of small business issuer in its charter)

 

Nevada   99-0363559

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

5151 Edina Industrial Blvd Suite 575

Edina, Minnesota 55439

(Address of principal executive offices)

 

(952) 405-6216

(Issuer’s telephone number)

 

Securities registered pursuant to Section 12(g) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001   PETV   OTC Markets Group, Inc. (OTCQB)

 

Common Stock, $0.001

(Title of Class)

 

Indicate by check mark whether the issuer: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files. Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

 

  Large accelerated filer ☐ Accelerated filer ☐
  Non-accelerated filer ☒ Smaller reporting company ☒
      Emerging Growth Company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the most practicable date:

 

Class   Outstanding as of November 16, 2026
Common Stock, $0.001   38,536,433

 

 

 

 

 

 

EXPLANATORY NOTE

 

Revision of Previously Issued Financial Statements

 

During the preparation of its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, PetVivo Holdings, Inc. (the “Company”) identified an error in its previously issued unaudited interim financial statements as of and for the three and six months ended September 30, 2025, which were included in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2025. The error related to the Company’s accounting for the June 30, 2025 amendment of certain convertible notes. The Company previously recognized a beneficial conversion feature as a debt discount with a corresponding increase to additional paid-in capital. ASU 2020-06 eliminated the separate beneficial conversion feature recognition model, and the guidance was effective for the Company before the amendment. Accordingly, the Company corrected the error by removing the beneficial conversion feature and the related amortization of the debt discount.

 

For the year ended March 31, 2026, the correction eliminated $786,908 previously recorded as a beneficial conversion feature including $23,649 related to warrants issued with promissory notes. As a result, additional paid-in capital was reduced by a net $763,259, from $103,584,614 to $102,821,355, and accumulated deficit was reduced by $763,259, from $102,075,765 to $101,312,506. The correction also reduced interest expense and net loss for the year ended March 31, 2026 by $763,259. Because the amortization was recorded in September 2025, the nine months ended December 31, 2025 were also affected and will be revised when presented in future filings. The correction had no effect on cash, total assets, total liabilities, total stockholders’ equity, or net cash used in operating activities as of and for the year ended March 31, 2026, as reported in Form 10-K filed on June 29, 2026. The March 31, 2026 amounts presented in these interim financial statements have been revised.

 

The Company previously recognized a beneficial conversion feature associated with the amended notes as a debt discount with a corresponding increase to additional paid-in capital. Accounting Standards Update No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), eliminated the separate recognition model for beneficial conversion features and was effective for the Company before the June 30, 2025 amendment. Accordingly, the conversion feature should not have been separately recognized as a beneficial conversion feature.

 

The Company has revised its previously issued unaudited interim financial statements as of and for the three and six months ended September 30, 2025, to remove the beneficial conversion feature. The revision:

 

● removed $763,259 previously presented as a beneficial conversion feature in the statement of changes in stockholders’ equity;
   
● reduced interest expense, total other income (expense), loss before taxes, net loss, and net loss available to common stockholders by $763,259 in the statement of operations for the three and six months ended  September 30, 2025;
   
● additional paid-in capital and accumulated deficit were each reduced by $763,259 as of September 30, 2025, with no effect on total equity;
   
● reduced net loss and amortization of debt discount by $763,259 in the statement of cash flows for the six months ended September 30, 2025 and;
   
● revised the related convertible-note disclosures.

 

The comparative financial information for the three and six months ended September 30, 2025 presented in this Quarterly Report on Form 10-Q have been revised to reflect the correction. The effects of the revision are described further in Note 1, “Summary of Significant Accounting Policies and Organization, and Note 1(R) Revision of Error in Previously Issued Financial Statements,” and Note 9, “Convertible Notes Payable and Accrued Interest,” to the unaudited condensed consolidated financial statements included in this report.

 

2

 

 

PETVIVO HOLDINGS, INC.

FORM 10-Q

FOR THE PERIOD ENDED September 30, 2026

 

INDEX

 

  Page
   
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 4
     
PART I. FINANCIAL INFORMATION 5
     
Item 1. Financial Statements 5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 27
Item 3. Qualitative and Quantitative Disclosures About Market Risk 32
Item 4. Controls and Procedures 32
   
PART II. OTHER INFORMATION 33
   
Item 1. Legal Proceedings 33
Item 1A. Risk Factors 33
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 33
Item 3. Defaults Upon Senior Securities 34
Item 4. Mine Safety Disclosure 34
Item 5. Other information 34
Item 6. Exhibits 34
     
SIGNATURES 35

 

3

 

 

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

 

Information included in this Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). This information may involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of PetVivo Holdings, Inc. (the “Company”), to be materially different from future results, performance, or achievements expressed or implied by any forward-looking statements. Forward-looking statements, which involve assumptions and describe future plans, strategies, and expectations of the Company, are generally identifiable by use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. These forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that the projections included in these forward-looking statements will come to pass. Actual results of the Company could differ materially from those expressed or implied in the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in “Risk Factors” included in documents we file from time to time with the U.S. Securities and Exchange Commission (the “SEC’), including our Annual Report on Form 10-K for our fiscal year ended March 31, 2026, (“2026 10-K Report”) and risks described in other SEC filings. Except as required by applicable laws, the Company has no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

 

4

 

 

PART I.

 

ITEM 1. FINANCIAL STATEMENTS

 

PETVIVO HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

  

September 30, 2026

(Unaudited)

   March 31, 2026
(As Revised)
 
         
Assets:          
Current Assets          
Cash  $16,287   $200,782 
Accounts receivable, net of allowance for credit losses   32,417    100,843 
Subscriptions receivable   -    600,000 
Inventory   314,818    538,366 
Prepaid expenses and other current assets   334,023    269,930 
Total Current Assets   697,545    1,709,921 
           
Property and Equipment, net   447,559    448,881 
           
Other Assets:          
Operating lease right-of-use assets   103,170    54,711 
Patents and trademarks, net   20,000    20,509 
Licensing Agreement, net   714,889    1,179,889 
Investments   150,000    150,000 
Security deposit   12,830    12,830 
Total Other Assets   1,000,889    1,417,939 
Total Assets  $2,145,993   $3,576,741 
           
Liabilities and Stockholders’ Equity:          
           
Current Liabilities          
Accounts payable  $718,082   $547,421 
Accrued expenses   186,984    453,713 
Operating lease liabilities – current portion   55,446    54,711 
Notes payable and accrued interest of related parties– current portion   1,296,850    321,447 
Total Current Liabilities   2,257,362    1,377,292 
           
Other Liabilities          
Operating lease liabilities (net of current portion)   47,724    - 
Total Other Liabilities   47,724    - 
           
Total Liabilities   2,305,086    1,377,292 
           
Commitments and Contingencies (Note 12)   -    - 
           
Stockholders’ Equity:          
Preferred Stock, par value $0.001 per share, 20,000,000 shares authorized:          
Series B Preferred stock: 5,000,000 shares issued and outstanding at September 30, 2026 and March 31, 2026   5,000    5,000 
           
Common Stock, par value $0.001, 250,000,000 shares authorized, 38,129,645 and 35,849,919 issued and outstanding at September 30, 2026 and March 31, 2026, respectively   38,130    35,850 
Common stock to be issued   46,000    649,750 
Additional Paid-In Capital   104,874,702    102,821,355 
Accumulated Deficit   (105,122,925)   (101,312,506)
Total Stockholders’ Equity (Deficit)   (159,093)   2,199,449 
Total Liabilities and Stockholders’ Equity  $2,145,993   $3,576,741 

 

See accompanying notes to these unaudited condensed consolidated financial statements.

 

5

 

 

PETVIVO HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

             
  

Three Months Ended

September 30,

   Six Months Ended
September 30,
 
   2026  

2025

(As Revised)

   2026   2025
(As Revised)
 
Revenues  $212,806   $303,284   $550,377   $600,784 
                     
Cost of Sales   16,731    83,226    130,985    194,000 
Gross Profit   196,075    220,058    419,392    406,784 
                     
Operating Expenses:                    
                     
Sales and Marketing   645,933    787,262    1,277,238    1,408,974 
Loss on Termination of License Agreement   

237,530

    -    

237,530

    - 
Research and Development   322,296    261,433    555,714    601,946 
General and Administrative   921,321    1,236,730    1,888,764    2,305,547 
                     
Total Operating Expenses   2,127,080    2,285,425    3,959,246    4,316,467 
                     
Operating Loss   (1,931,005)   (2,065,367)   (3,539,854)   (3,909,683)
                     
Other (Expense) Income                    
Loss on Lease Termination   -    -    -    (149,125)
Unrealized Loss on Change in Derivative Liabilities   -    -    -    (320,404)
Other Income   -    -    -    111,517 
Interest Income   -    -    -    13,099 
Interest Expense   (15,526)   (179,183)   (20,565)   (300,991)
                     
Total Other Income (Expense)   (15,526)   (179,183)   (20,565)   (645,904)
                     
Loss before taxes   (1,946,531)   (2,244,550)   (3,560,419)   (4,555,587)
                     
Income Tax Provision   -    -    -    - 
                     
Net Loss   (1,946,531)   (2,244,550)   (3,560,419)   (4,555,587)
Less: Series B Preferred Stock Dividends   (125,000)   (125,000)   (250,000)   (153,603)
Net Loss Available to Common Stockholders  $(2,071,531)  $(2,369,550)  $(3,810,419)  $(4,709,190)
                     
Net Loss Per Share:                    
Basic and Diluted  $(0.05)  $(0.09)  $(0.10)  $(0.18)
                     
Weighted Average Common Shares Outstanding:                    
Basic and Diluted   38,023,703    27,579,136    37,542,128    25,949,915 

 

See accompanying notes to these unaudited condensed consolidated financial statements.

 

6

 

 

PETVIVO HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(UNAUDITED)

 

Three and Six Months Ended September 30, 2026

 

   Shares     Capital                
   Common
Stock
  

Series B

Preferred Stock

  

Additional

Paid-in

  

Common Stock

To Be

   Accumulated     
   Shares   Amount   Shares   Amount   Capital   Issued   Deficit   Total 
Balance at March 31, 2026   35,849,919   $35,850 -  5,000,000   $5,000   $102,821,355   $649,750   $(101,312,506)  $2,199,449 
Sale of common stock issued against subscription receivable   937,500    938    -    -    749,062    (600,000)   -    150,000 
Common stock issued for services   200,000    200    -    -    159,800    -    -    160,000 
Common stock issued to employees and directors for compensation   430,652    431    -    -    329,794    (49,750)   -    280,475 
Common stock to be issued for employees and directors for compensation   -    -    -    -    -    48,000    -    48,000 
Dividends declared on Series B preferred stock   -    -    -    -    -    -    (125,000)   (125,000)
Conversion of accrued dividends to common stock   176,174    176    -    -    124,824    -    -    125,000 
Stock based compensation   -    -    -    -    132,133    -    -    132,133 
Net loss   -    - -  -    -    -    -    (1,613,888)   (1,613,888)
Balance at June 30, 2026   37,594,245   $37,595 -  5,000,000   $5,000   $104,316,968   $48,000   $(103,051,394)  $1,356,169 
Sale of common stock   62,500    62    -    -    49,938    -    -    50,000 
Common stock issued for employees and directors for compensation   292,157    292    -    -    231,758    (48,000)   -    184,050 
Conversion of accrued dividends to common stock   156,250    156    -    -    124,844    -    -    125,000 
Dividends declared on Series B preferred stock   -    -    -    -    -    -    (125,000)   (125,000)
Conversion of accrued board compensation to common stock   12,628    13    -    -    8,574    -    -    8,587 
Conversion of stock options to common stock   11,865    12    -    -    8,056    -    -    8,068 
Common stock to be issued to employees and directors for compensation   -    -    -    -    -    46,000    -    46,000 
Stock based compensation   -    -    -    -    134,564    -    -    134,564 
Net loss   -    - -  -    -    -    -    (1,946,531)   (1,946,531)
Balance at September 30, 2026   38,129,645   $38,130 -  5,000,000   $5,000   $104,874,702   $46,000   $(105,122,925)  $(159,093)

 

Three and Six Months Ended September 30, 2025

 

   Shares      Shares      Shares             
   Common Stock   Series A Preferred Stock   Series B Preferred Stock  

Additional

Paid-in

   Accumulated     
   Shares   Amount   Shares   Amount   Shares   Amount   Capital
(As Revised)
   Deficit
(As Revised)
   Total 
Balance at March 31, 2025   24,181,537   $24,182    3,045,000   $3,045    5,000,000   $5,000   $95,385,511   $(91,198,490)  $4,219,248 
Common stock issued for services   60,000    60    -    -    -    -    40,360    -    40,420 
Common stock issued for conversion of A/P   8,000    8    -    -    -    -    5,992         6,000 
Warrant exercise   70,000    70    -    -    -    -    139,930    -    140,000 
Stock based compensation   -    -    -    -    -    -    133,197    -    133,197 
Vesting of restricted stock units   82,657    82    -    -    -    -    (82)   -    - 
Dividends declared on Series B preferred stock   -    -    -    -    -    -    -    (28,603)   (28,603)
Elimination of derivative liability (Note 9)   -    -    -    -    -    -    768,493    -    768,493 
Net loss   -    -    -    -    -    -    -    (2,311,037)   (2,311,037)
Balance at June 30, 2025   24,402,194   $24,402    3,045,000   $3,045    5,000,000   $5,000   $96,473,401   $(93,538,130)  $2,967,718 
Common stock issued for services   19,372    19    -    -    -    -    14,981    -    15,000 
Common stock issued to employees for compensation   707,669    708    -    -    -    -    557,953    -    558,661 
Conversion of Series A Preferred to common stock   3,045,000    3,045    (3,045,000)   (3,045)   -    -    -    -    - 
Conversion of accrued dividends to common stock   38,138    38    -    -    -    -    28,565    -    28,603 
Common stock issued for licensing agreement   1,000,000    1,000    -    -    -    -    799,000    -    800,000 
Vesting of restricted stock units   72,500    73    -    -    -    -    (73)   -    - 
Common stock issued for conversion of debt   3,669,806    3,670    -    -    -    -    2,014,484    -    2,018,154 
Dividends declared on Series B Preferred Stock   -    -    -    -    -    -    -    (125,000)   (125,000)
Warrants issued with promissory notes   -    -    -    -    -    -    23,649    -    23,649 
Stock based compensation   -    -    -    -    -    -    140,737    -    140,737 
Net loss   -    -    -    -    -    -    -    (2,244,550)   (2,244,550)
Balance at September 30, 2025   32,954,679   $32,955    -    -    5,000,000   $5,000   $100,052,697   $(95,907,680)  $4,182,972 

 

See accompanying notes to these unaudited condensed consolidated financial statements.

 

7

 

 

PETVIVO HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

       
   For the Six Months Ended 
   September 30, 2026
(Unaudited)
   September 30, 2025
(As Revised)
 
CASH FLOWS FROM OPERATING ACTIVITIES:          
           
Net Loss  $(3,560,419)  $(4,555,587)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:          
Stock-based compensation   833,290    832,594 
Depreciation and amortization   168,506    241,533 
Amortization of Right-of-Use asset   

32,112

   31,439 
Unrealized loss on change in fair value of derivatives        320,404 
Loss on lease termination        149,125 
Amortization of debt discount        173,293 
Common stock issued for services   160,000    55,420 
Non-cash loss on termination of licensing agreement   162,530    - 
Changes in Operating Assets and Liabilities          
Prepaid expenses and other current assets   (64,093)   (27,716)
Accounts receivable   68,426    (82,300)
Inventory   103,502    (254,789)
Accounts payable and accrued expenses   195,035    (786,183)
Lease liabilities   (32,112)   (31,439)
Accrued interest on notes payable   20,403    105,997 
Net Cash (Used In) Operating Activities   (1,912,820)   (3,828,209)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
Purchase of equipment   (26,675)   (12,929)
Payments received on disposal of equipment   -    4,874 
Security deposits and other assets   -    14,660 
Net Cash (Used in) Investing Activities   (26,675)   6,605 
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Proceeds received from common stock subscription receivable   600,000    - 
Proceeds from issuance of common stock   200,000    - 
Proceeds received from preferred stock subscription receivable   -    4,400,000 
Proceeds from the issuance of convertible debentures   -    160,000 
Proceeds from the exercise of warrants   -    140,000 
Proceeds from the issuance of notes payable   955,000    12,000 
Repayments of notes payable   -    (350,171)
Net Cash Provided by Financing Activities   1,755,000    4,361,829 
           
Net (Decrease)/increase in Cash   (184,495)   540,225 
Cash at Beginning of Period   200,782    227,689 
Cash at End of Period  $16,287   $767,914 
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:          
Cash Paid During The Period For:          
Interest  $-   $21,701 
SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING AND INVESTING ACTIVITIES          
(Decrease) increase to operating lease right of use asset and operating lease liability  $80,571   $(859,504)
Vesting of restricted stock units  $-   $155 
Stock issued for conversion of accounts payable and accrued board compensation  $8,587   $6,000 
Dividends declared on Series B preferred stock  $250,000   $153,603 
Convertible debentures and accrued interest converted to common stock  $-   $2,018,154 
Stock issued for licensing agreement  $-   $800,000 
Stock issued for conversion of accrued dividends  $250,000   $28,603 
Derecognition of VetStem License  $325,000   $- 
Inventory reduction with termination of VetStem license  $

120,046

   $- 
Liabilities forgiven with termination of VetStem license  $

(282,516

)  $- 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

8

 

 

PetVivo Holdings, Inc.

Notes to Financial Statements

September 30, 2026

(Unaudited)

 

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION

 

(A) Organization and Description

 

PetVivo Holdings, Inc. was incorporated in Nevada under its former name in 2009 and entered its current business in 2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in PetVivo, Inc. becoming a wholly owned subsidiary of PetVivo Holdings, Inc. In April 2017, PetVivo Holdings, Inc. acquired another Minnesota corporation, Gel-Del Technologies, Inc., through a statutory merger, which is also a wholly-owned subsidiary of PetVivo Holdings, Inc. In April 2025, PetVivo Holdings, Inc. changed the name of its wholly-owned subsidiary PetVivo, Inc. to PetVivo Animal Health, Inc. to better reflect the industry in which PetVivo Holdings, Inc. sells its products.

 

The Company is in the business of licensing and commercializing our proprietary medical devices and biomaterials for the treatment and/or management of afflictions and diseases in animals, initially for dogs and horses. The Company began commercialization of its lead product Spryng® with OsteoCushion® Technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses in September 2021. The Company has a pipeline of additional products for the treatment of animals in various stages of development. The Company currently has six (6) U.S. and four (4) foreign patents issued, with two (2) additional patent applications pending with the United States Patent and Trademark Office. The patents protect the Company’s biomaterials, products, production processes and methods of use. In February 2025, The Company signed an exclusive licensing agreement with VetStem, Inc. to market and sell their PrecisePRP™ (Platelet-Rich Plasma) product for both canine and equine. On July 24, 2026, the Company terminated the licensing agreement with VetStem, Inc.

 

The Company’s operations are conducted from its headquarter facilities in suburban Minneapolis, Minnesota with an outsourced distribution location in St. Joseph, Missouri.

 

(B) Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (US GAAP) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X and ASC 270-10-50. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete annual financial statements. 

 

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the interim periods presented are not necessarily indicative of the results that may be expected for the full fiscal year. These interim condensed financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the company’s annual report on Form 10-K for the fiscal year ended March 31, 2026.

 

Certain prior-period amounts have been reclassified to conform to the current-period presentation. These reclassifications had no effect on previously reported net income, total assets, total liabilities, or stockholders’ equity.

 

(C) Principles of Consolidation

 

The accompanying consolidated financial statements include all the accounts of PetVivo Holdings, Inc., and its four wholly owned corporations, Gel-Del Technologies, Inc., PetVivo Animal Health, Inc., Somatrix Technologies, Inc. (previously Cosmeta Corp) and PetVivo AI, Inc. (collectively, the “Company”). All intercompany transactions have been eliminated upon consolidation.

 

The Company is an emerging growth company as the term is used in The Jumpstart Our Business Startups Act, enacted on April 5, 2012 and has elected to comply with certain reduced public company reporting requirements.

 

(D) Use of Estimates

 

In preparation of the consolidated financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include allowance for credit losses, inventory obsolescence, estimated useful lives and potential impairment of property and equipment and intangibles, estimate of fair value of share-based payments, distributor rebate payable, provision for product returns, right of use lease assets and liabilities and valuation of deferred tax assets.

 

9

 

 

(E) Cash and Cash Equivalents

 

The Company considers all highly-liquid, temporary cash investments with original maturity of three months or less to be cash equivalents. The Company had no cash equivalents at September 30, 2026.

 

(F) Concentration Risk

 

The Company maintains its cash with various financial institutions, which at times may exceed federally insured limits. At September 30, 2026, the Company did not have cash balances in excess of the federally insured limits.

 

(G) Accounts Receivable

 

Accounts receivable is carried at its contractual amounts, less an estimated allowance for credit losses. Management estimates the credit losses using a loss-rate approach based on historical loss information, adjusted for management’s expectations about current and future economic conditions, as the basis to determine expected credit losses. Management exercises significant judgment in determining expected credit losses. Key inputs include macroeconomic factors, industry trends, the creditworthiness of counterparties, historical experience, the financial conditions of the customers, and the amount and age of past due accounts. Management believes that the composition of receivables is consistent with historical conditions as credit terms and practices and the client base has not changed significantly. Receivables are considered past due if full payment is not received by the contractual due date. Past due accounts are generally written off against the allowance for credit losses only after all collection attempts have been exhausted. As of September 30, 2026 and March 31, 2026, the Company had not recorded an allowance for credit losses, as management determined that no allowance was necessary based on its assessment of the collectability of outstanding balances and the credit quality of its customers.

 

(H) Inventory

 

Inventory is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (FIFO) method. Inventory consists of raw materials, work-in-process and finished goods.

 

The Company evaluates inventory for excess, and obsolescence based on factors such as current inventory levels, estimated product life cycles, historical and forecasted customer demand, and input from the product development team. When necessary, an inventory write-off is recorded to reduce the carrying value of inventory to its estimated net realizable value. These estimates and assumptions are reviewed quarterly and annually and updated as needed based on the Company’s business plans and market conditions.

 

(I) Property & Equipment

 

Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method (after considering their respective estimated residual values) over the assets estimated useful life of 3 to 5 years for production and computer equipment and furniture. Leasehold improvements are depreciated using the straight-line method over the shorter of the estimated useful lives of the improvements or the remaining lease term (including renewal periods that are reasonably certain to be exercised).

 

10

 

 

(J) Patents and Trademarks

 

The Company capitalizes direct costs for the maintenance and advancement of their patents and trademarks and amortizes these costs over the lesser of the useful life of 60 months or the legal life of the patent. The Company evaluates the recoverability of intangible assets periodically by considering events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired. The Company has chosen to amortize over a sixty (60) month period, as the patent assets are expected to generate economic benefits for only five (5) years.

 

(K) Loss Per Share

 

The Company calculates earnings (loss) per share (“EPS”) in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260, Earnings Per Share. Basic EPS is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. For the six months ended September 30, 2026 and 2025, the Company reported a net loss; therefore, diluted EPS is calculated the same as basic EPS, as the inclusion of all potentially dilutive securities would be anti-dilutive.

 

The following securities were excluded from the calculation of diluted loss per share because their effect would have been anti-dilutive:

 

  ● Options and warrants: 11,573,023 shares (2026); 14,974,081 shares (2025)
  ● Series B Preferred Shares if Converted into Common Stock: 5,000,000 shares (2026 and 2025)
  ● Unvested RSUs: 0 shares (2026); 205,314 shares (2025)

 

(L) Revenue Recognition

 

The Company recognizes revenue in accordance with FASB ASC 606 “Revenue from Contracts with Customers.”

 

The Company derives revenue from the sale of its pet care products directly to its veterinarian customers in the United States. The Company recognizes revenue when performance obligations under the terms of a contract with the veterinarian customer are satisfied. Product sales occur once control or title is transferred based on the commercial terms. Revenue is recognized upon delivery to the customer, which is when control of these products is transferred and in an amount that reflects the consideration the Company expects to receive for these products. Shipping costs charged to customers are reported as an offset to the respective shipping costs. The Company does not have any significant financing components as payment is received at or shortly after the point of sale.

 

The Company entered into a Distribution Services Agreement (the “Agreement”) with MWI Veterinary Supply Co. (the “Distributor”) on June 17, 2022. Contracts with the Distributor are evidenced by individual executed purchase orders subject to the terms of the Agreement. The contracts consist of a single performance obligation related to the sale of our pet care products. Product sales occur once control or title is transferred based on the commercial terms in the Agreement. Revenue is recognized upon delivery to the Distributor; payment is due within 60 days. The Agreement provides for a distribution fee payable to the Distributor equal to 5% of gross monthly sales payable in 45 days; the distribution fee is netted against revenue. The Agreement provides for a rebate payable to the Distributor based on annual sales volume that is retroactively applied. The rebate is estimated under the expected value method and is netted against revenue. Sales are subject to various right of return provisions.

 

As of February 2025, the distribution agreement expired with MWI Veterinary Supply Co. At that time, the Company had a rebate liability of $57,264 and a distribution fee payable of $2,299. These liabilities should have been reversed in fiscal 2025. The Company recorded the reversal of the $57,264 rebate liability and $2,299 distribution fee payable in the quarter ended September 30, 2026 as an out-of-period adjustment, which management concluded was not material. As a result, the Company no longer has any distribution fees, rebates or return liabilities recorded during the six-month period ending September 30, 2026.

 

The Company uses an expected value method to estimate returns and has determined that any returns would be immaterial as of September 30, 2026 and March 31, 2026. As a result, there is no return liability recorded. Shipping and handling costs are a fulfillment activity and are reported as cost of sales.

 

11

 

 

Assets and liabilities (included in accrued expenses) under the Agreement were as follows:

 

   September 30, 2026   March 31, 2026 
Accounts receivable  $      -   $- 
Rebate liability   -    57,264 
Distribution fee payable   -    2,299 

 

We currently don’t have any distributor agreements in place, as of September 30, 2026. Product sales for all domestic shipments into the United States occur once control or title is transferred based on the commercial terms purchase orders. Revenue is recognized upon delivery to the Distributor in the United States. With international shipments, freight terms are FOB our warehouse, as ownership transfers for these international shipments at the point of freight pickup from our warehouse. Payments are due within 30 days for domestic orders and payments are in-advance for international distributors.

 

From time-to-time, we honor returns for short-dated inventory (close to expiration). Inasmuch, sales periodically are subject to returns; the Company uses an expected value method to estimate returns and has determined that any returns would be immaterial as of September 30, 2026 and March 31, 2026. As a result, there is no return liability recorded. Shipping and handling costs are a fulfillment activity and are reported as cost of sales.

 

In December 2024, the Company entered into new wholesale distribution partnerships with Vedco, Inc. (“Vedco”) and Clipper Distributing, LLC (“Clipper”). A distribution service agreement was not signed with either distribution partner. Contracts with both distribution partners are evidenced by individual executed purchase orders. The purchase orders consist of a single performance obligation related to the sale of our pet care products. Product sales occur once control or title is transferred based on the terms in the purchase order. Revenue is recognized upon delivery to the Distributor for domestic shipments, and for international shipments, ownership transfers at the point of freight pickup from our warehouse, at which time we recognize the revenue for these international customers; payment is due within 30 days. Neither distribution partnership provides for a distribution fee payable or a rebate payable.

 

For the three months ended September 30, 2026 and 2025, the Company recognized revenue from product sales to Vedco of $97,252 and $227,498, respectively. This represents 46% and 75% of total revenues for the three months ended September 30, 2026 and 2025, respectively. Additional revenues incurred were $39,549 and $0 for the three months ended September 30, 2026 and 2025 from Clipper Distributing. This represents 19% and 0% of total revenues for the three months ended September 30, 2026 and 2025, respectively.

 

Revenues were $212,806 and $303,284 for the three months ended September 30, 2026 and 2025, respectively. Revenues in the three months ended September 30, 2026, consist of sales of our Spryng® products of $149,573; PrecisePRP™ products of $6,941; and $57,264 from the reversal of a rebate liability under a distribution agreement that expired in February 2025, offset by sales discounts of ($973). The liability should have been reversed in fiscal 2025 and was recorded in the current quarter as an out-of-period adjustment, which management concluded was not material to any period. Excluding this adjustment, revenues decreased 49% for the three months ended September 30, 2026 compared to the three months ended September 30, 2025. Revenues in the three months ended September 30, 2025, consisted of sales of our Spryng® products of $186,902 and PrecisePRP™ products of $116,382. The decrease in our revenues in the three months ended September 30, 2026, compared to the three months ended September 30, 2025, is due to decreased PrecisePRP™ product sales as a result of the termination of our VetStem licensing agreement on July 24, 2026.

 

For the six months ended September 30, 2026 and 2025, the Company recognized revenue from product sales to Vedco of $331,875 and $425,878, respectively. This represents 60% and 71% of total revenues for the six months ended September 30, 2026 and 2025, respectively. Additional revenues incurred were $79,746 and $0 for the six months ended September 30, 2026 and 2025 from Clipper Distributing. This represents 14% and 0% of total revenues for the six months ended September 30, 2026 and 2025, respectively.

 

Revenues were $550,377 and $600,784 for the six months ended September 30, 2026 and 2025, respectively. Revenues for the six months ended September 30, 2026, consist of sales of our Spryng® products of $358,393; PrecisePRP™ products of $136,017; and $57,264 from the reversal of a rebate liability under a distribution agreement that expired in February 2025, offset by sales discounts of ($1,297). The liability should have been reversed in fiscal 2025 and was recorded in the current quarter as an out-of-period adjustment, which management concluded was not material to any period. Excluding this adjustment, revenues decreased 18% for the six months ended September 30, 2026 compared to the six months ended September 30, 2025. Revenues in the six months ended September 30, 2025, consisted of sales of our Spryng® products of $335,145 and PrecisePRP™ products of $265,639. The decrease in our revenues in the six months ended September 30, 2026, compared to the six months ended September 30, 2025, is due to sales of PrecisePRP™ products, pursuant to the termination of our licensing agreement with VetStem.

 

Accounts receivable from Vedco was $24,313 and $83,494 at September 30, 2026, and March 31, 2026.

 

(M) Research and Development

 

The Company expenses research and development costs as incurred.

 

(N) Fair Value of Financial Instruments

 

FASB ASC 820, Fair Value Measurements and Disclosures (“ASC 820”) establishes a framework for all fair value measurements and expands disclosures related to fair value measurement and developments. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 requires that assets and liabilities measured at fair value are classified and disclosed in one of the following three categories:

 

  ● Level 1 - quoted market prices in active markets for identical assets or liabilities.
     
  ● Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
     
  ● Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

12

 

 

The carrying amounts of the Company’s financial instruments, such as cash, accounts receivable, accounts payable and other liabilities approximate their fair value as of September 30, 2026 and March 31, 2026, due to the short-term nature of these items.

 

The fair value of the Company’s debt approximates its carrying value as of September 30, 2026 and March 31, 2026, because the stated interest rates and terms of the debt are consistent with those currently available to the Company for similar instruments.

 

(O) Stock-Based Compensation

 

The Company accounts for stock-based compensation under the provisions of FASB ASC 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. In accordance with ASU No. 2018-07, Compensation – Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting share-based payment transactions for acquiring goods and services from nonemployees are included. Consistent with the accounting requirement for employee share-based payment awards, nonemployee share-based payment awards within the scope of Topic 718 are measured at grant-date fair value of the equity instruments that an entity is obligated to issue when the good has been delivered or the service has been rendered and any other conditions necessary to earn the right to benefit from the instruments have been satisfied.

 

Stock compensation of $833,290 for the period ending September 30, 2026 consisted of: i) employee stock awards $474,525; ii) board of directors compensation $84,000; iii) exchange of stock options for common stock of $8,068; and iv) warrant expense $266,697.

 

(P) Income Tax Provision

 

The Company is subject to income taxes in the U.S. The determination of these tax liabilities requires estimation, significant judgment, and interpretation of U.S. federal and state tax statutes, regulations, and case laws. Additionally, governing tax legislation could change significantly with little or no notice. It is important for us to monitor economic, political, and other conditions in the various countries with operations as changes in a jurisdiction’s conditions could impact the amount of deferred tax assets or our ability to utilize deferred tax assets in the future.

 

The Company accounts for income taxes in accordance with FASB ASC 740, Income Taxes, using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the consolidated financial statement carrying amounts and the tax bases of assets and liabilities, as well as for net operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates and laws expected to apply when the related temporary differences reverse or the carryforwards are utilized. The Company establishes a valuation allowance to reduce deferred tax assets to the amount expected to be realized when, based on the available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. For the current period ending September 30, 2026 the Company has recorded a full valuation allowance against its deferred tax assets.

 

As required by FASB ASC 740, Income Taxes, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties related to unrecognized income tax benefits in the provision for income tax expense. See Note 17.

 

The Company is not currently under examination by any federal or state jurisdiction.

 

(Q) Recently Issued Accounting Pronouncements

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. This ASU is effective for public entities with fiscal years beginning after December 15, 2024. The Company adopted this guidance for the year ended March 31, 2026 and applied the guidance on a retrospective basis. The adoption did not have a material impact on the consolidated financial statements. Refer to Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations in the Recently Issued Accounting Pronouncements section for further details.

 

In November 2024, the FASB issued ASU 2024-03, which requires public entities to disaggregate certain expense categories in the notes to the financial statements. The standard is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption allowed. The Company is currently evaluating the impact of this guidance on its financial statement disclosures, but does not anticipate it will affect its results of operations or cash flows.

 

Effective April 1, 2026, the Company adopted ASU 2025-05, “Financial Instruments—Credit Losses (Topic 326): Amendments to the Measurement of Credit Losses for Short-Term Receivables.” The update provides a practical expedient that permits an entity to assume that current economic conditions as of the balance sheet date remain unchanged over the remaining life of the asset, thereby removing the requirement to incorporate future macroeconomic forecasts for qualifying short-term accounts receivable and contract assets arising from revenue transactions.

 

The Company elected to apply the practical expedient prospectively to all current accounts receivable and contract assets within the scope of the guidance. The adoption of ASU 2025-05 did not have a material impact on our Condensed Consolidated Financial Statements and related footnote disclosures.

 

13

 

 

(R) Revision of Error in Previously Issued Financial Statements

 

The Company identified an error in its accounting for the June 30, 2025 amendment of certain convertible notes. The Company previously recognized a beneficial conversion feature as a debt discount with a corresponding increase to additional paid-in capital. ASU 2020-06 eliminated the separate beneficial conversion feature recognition model, and the guidance was effective for the Company before the amendment. Accordingly, the Company corrected the error by removing the beneficial conversion feature and the related amortization of the debt discount.

 

For the year ended March 31, 2026, the correction eliminated $786,908 previously recorded as a beneficial conversion feature including $23,649 related to warrants issued with promissory notes. As a result, additional paid-in capital was reduced by a net $763,259, from $103,584,614 to $102,821,355, and accumulated deficit was reduced by $763,259, from $102,075,765 to $101,312,506. The correction also reduced interest expense and net loss for the year ended March 31, 2026 by $763,259. Because the amortization was recorded in September 2025, the nine months ended December 31, 2025 were also affected and will be revised when presented in future filings. The correction had no effect on cash, total assets, total liabilities, total stockholders’ equity, or net cash used in operating activities as of and for the year ended March 31, 2026. The March 31, 2026 amounts presented in these interim financial statements have been revised.

 

For the six months ended September 30, 2025, the correction eliminated $763,259. As a result, additional paid-in capital was reduced by a net of $763,259 from $100,815,956 to $100,052,697 and accumulated deficit was reduced from $96,670,939 to $95,907,680. In September 2025, the amortization of the debt discount recorded to interest expense of $763,259 was removed. As a result, interest expense was reduced by $763,259 from $1,064,250 to $300,991, other income (expense) was reduced by $763,259 from $1,409,162 to $645,904, loss before taxes and net loss were reduced by $763,259 from $5,318,846 to $4,555,587, and net loss available to common stockholders was reduced by $763,259 from $5,472,449 to $4,709,190. The correction had no effect on cash, total assets, total liabilities, total stockholders’ equity, or net cash used in operating activities as of and for the six months ended September 30, 2025. The September 30, 2025 amounts presented in these interim financial statements have been revised.

 

The following tables summarize the effect of the errors on the Company’s audited consolidated balance sheets as of March 31, 2026 and unaudited consolidated balance sheet as of September 30, 2025:

 

  

March 31, 2026

As Previously Reported

   Adjustment  

March 31, 2026

As Revised

 
             
Audited consolidated balance sheets - Additional Paid-In Capital  $103,584,614   $(763,259)  $102,821,355 
Audited consolidated statements of changes in stockholders’ equity – Beneficial conversion feature   786,908    (786,908)   - 
Audited consolidated statements of changes in stockholders’ equity – Warrants issued with promissory notes   -    23,649    23,649 
Audited consolidated balance sheets - Accumulated Deficit   (102,075,765)  $763,259    (101,312,506)

 

  

September 30, 2025

As Previously Reported

   Adjustments  


September 30, 2025

As Revised

 
             
Unaudited condensed consolidated balance sheets – Additional Paid-In Capital  $100,815,956   $(763,259)  $100,052,697 
Unaudited condensed consolidated balance sheets – Accumulated Deficit   (96,670,939)   763,259   (95,907,680)

 

                
Unaudited consolidated statements of operations for the three months ended – Interest Expense   (942,442)   763,259    (179,183)
Unaudited consolidated statements of operations for the three months ended – Total Other Income (Expense)   (942,442)   763,259    (179,183)
Unaudited consolidated statements of operations for the three months ended – Loss before taxes   (3,007,809)   763,259    (2,244,550)
Unaudited consolidated statements of operations for the three months ended – Net Loss   (3,007,809)   763,259    (2,244,550)
Unaudited consolidated statements of operations for the three months ended – Net Loss Available to Common Stockholders   (3,132,809)   763,259    (2,369,550)
Unaudited consolidated statements of operations for the three months ended – Net Loss Per Share, Basic and Diluted     (0.11 )     0.02       (0.09 )

 

                
Unaudited consolidated statements of operations for the six months ended – Interest Expense   (1,064,250)   763,259    (300,991)
Unaudited consolidated statements of operations for the six months ended – Total Other Income (Expense)   (1,409,162)   763,259    (645,904)
Unaudited consolidated statements of operations for the six months ended – Loss before taxes   (5,318,846)   763,259    (4,555,587)
Unaudited consolidated statements of operations for the six months ended – Net Loss   (5,318,846)   763,259    (4,555,587)
Unaudited consolidated statements of operations for the six months ended – Net Loss Available to Common Stockholders   (5,472,449)   763,259    (4,709,190)
Unaudited consolidated statements of operations for the six months ended – Net Loss Per Share, Basic and Diluted     (0.21 )     0.03       (0.18 )
Unaudited consolidated statements of changes in stockholders’ equity – Beneficial conversion feature   763,259    (763,259)   - 
Unaudited consolidated statements of changes in stockholders’ equity – Additional Paid-In Capital   100,815,956    (763,259)   100,052,697 
Unaudited consolidated statements of changes in stockholders’ equity – Accumulated Deficit   (96,670,939)   763,259   (95,907,680)
Unaudited consolidated statements of cash flows – Net Loss   (5,318,846)   763,259    (4,555,587)
Unaudited consolidated statements of cash flows – Amortization of debt discount   936,552    (763,259)   173,293 

 

While the adjustments changed additional paid-in capital and accumulated deficit line items in the unaudited condensed consolidated balance sheets, they did not have an impact on total net cash used in operating activities, net cash used in investing activities, or net cash provided by financing activities.

 

The related notes to the unaudited condensed consolidated financial statements have also been revised to reflect the error corrections described above.

 

14

 

 

NOTE 2 – INVENTORY

 

Inventory consists of the following at September 30, 2026, and March 31, 2026:

 

The inventory components are as follows:

 

   September 30, 2026   March 31, 2026 
Finished Goods  $92,508   $291,218 
Work in process   23,175    21,850 
Raw materials   199,135    225,298 
Total Net  $314,818   $538,366 

 

As of March 31, 2026, the Company recorded an inventory allowance of $239,935 for the current market conditions with its licensed PrecisePRP™ (Platelet-Rich Plasma) product whereby the PrecisePRP product had not been selling as originally expected. Therefore, management decided to sell the PrecisePRP product line at a discount, so as to reduce the inventory levels, resulting in the Company recording an inventory allowance of $239,935. On July 24, 2026, the Company terminated its licensing agreement with VetStem, Inc. PrecisePRP finished goods valued at $359,981 and inventory allowances of $239,935 for a net inventory of $120,046 have been written off as of July 24, 2026.

 

NOTE 3 – PREPAID EXPENSES AND OTHER CURRENT ASSETS

 

As of September 30, 2026, the Company had $334,023 in prepaid expenses and other current assets consisting primarily of $24,000 in investor relations, $215,000 in insurance costs, $48,000 in software subscription fees, $24,000 in OTC Markets and FINRA fees, and $21,000 in trade shows.

 

As of March 31, 2026, the Company had $269,930 in prepaid expenses and other current assets consisting primarily of $102,000 in insurance costs, $72,000 in prepaid investor relations expenses, $47,000 in software subscription fees, $36,000 in OTC markets and FINRA fees, and $9,000 in consulting fees

 

NOTE 4 – PROPERTY AND EQUIPMENT

 

Property and equipment consists of the following at September 30, 2026, and March 31, 2026:

 

   September 30, 2026   March 31, 2026 
Leasehold improvements  $258,099   $258,099 
Production equipment   619,229    619,229 
R&D equipment   25,184    25,184 
Computer equipment and furniture   181,981    155,306 
Total, at cost   1,084,493    1,057,818 
Accumulated depreciation   (636,934)   (608,937)
Total Net  $447,559   $448,881 

 

Depreciation expense was $13,836 and $17,661 for the three months ended September 30, 2026 and 2025, respectively. Depreciation expense was $27,997 and $34,321 for the six months ended September 30, 2026 and 2025, respectively.

 

15

 

 

NOTE 5 – PATENTS AND TRADEMARKS

 

The components of patents and trademarks, all of which are finite lived, were as follows:

 

   September 30, 2026   March 31, 2026 
Patents  $3,870,057   $3,870,057 
Trademarks   26,142    26,142 
Total at cost   3,896,199    3,896,199 
Accumulated Amortization   (3,876,199)   (3,875,690)
Total net  $20,000   $20,509 

 

Amortization expense was $0 and $870 for the three months ended September 30, 2026 and 2025, respectively. Amortization expense was $509 and $2,100 for the six months ended September 30, 2026 and 2025, respectively.

The Company currently has six (6) U.S. and four (4) foreign patents issued, with two (2) additional patent applications pending with the United States Patent and Trademark Office.

 

NOTE 6 –LICENSING AGREEMENTS

 

The components of licensing agreements, all of which are finite-lived, were as follows:

 

   September 30, 2026   March 31, 2026 
License Agreements  $800,000   $2,800,000 
Accumulated Impairment Losses   -    (1,000,000)
Contract Payable   -    

(125,000

)
Accumulated Amortization   (85,111)   (495,111)
Total net  $714,889   $1,179,889 

 

In February 2025, the Company signed an exclusive licensing agreement with VetStem, Inc. to market and sell their PrecisePRP™ (Platelet-Rich Plasma) for both canine and equine products. The exclusive licensing agreement is a five-year agreement whereby the Company paid an initial licensing fee of $2,000,000, which was paid in a combination of $500,000 cash, $1,000,000 in stock issuances and $500,000 in future contract payments. The Company paid $125,000 in contract payments in August 2025 and $125,000 in November 2025. Future contract payments included in accrued expenses as of September 30, 2026 and March 31, 2026 were $0 and $125,000, respectively, after $125,000 was derecognized. The $500,000 Contract Payable reconciliation: $250,000 paid (August and November 2025), $125,000 derecognized at March 31, 2026, and $125,000 accrued at March 31, 2026 and forgiven at termination in July 2026.

 

The licensing fee is amortized over sixty (60) months, the term of the agreement. The licensing agreement also has a nominal royalty fee payment between 3% to 4.5%, commencing in the seventh month of the licensing agreement. The royalty fee expense for the three months ended September 30, 2026, and 2025 was $0 and $2,060, respectively. The royalty fee expense for the six months ended September 30, 2026, and 2025 was $3,872 and $2,060, respectively. The Company also issued 250,000 warrants, with a strike price of $1.25 per share for a term of three years. The total warrant expense is fair valued at $46,030 to be amortized over thirty-six months. The Company used the Black-Scholes option pricing model to calculate the warrant fair value, with the following assumptions: no dividend yield, expected volatility of 115.1%, risk free interest rate of 4.02%, and expected warrant life of 3 years. During the three months ended September 30, 2026 and 2025, warrant expense was $3,836 and $3,836, respectively. During the six months ended September 30, 2026 and 2025, warrant expense was $7,672 and $7,672, respectively.

 

As of March 31, 2026, the Company decided the long-term viability of selling the VetStem PrecisePRP products was not in the Company’s best interests, as the market is not accepting the PRP product as expected. The Company sent VetStem a Notice of Termination for the license agreement, along with a transition period to move the remaining inventory within a six-to-nine-month period. This licensing agreement Notice of Termination effectively reduces the licensing agreement from 60 months to 24 months, resulting in a licensing agreement impairment expense for the reduction of the licensing period. As of March 31, 2026, the Company recorded an impairment expense of $1,000,000. As a result of termination negotiations, the Company derecognized the $125,000 final milestone payment obligation, resulting in a corresponding reduction of the related contract payable. On July 24, 2026, the Company terminated the license agreement with VetStem. As of September 30, 2026, the Company has written off the licensing agreement of $2,000,000, accumulated impairment losses of $1,000,000, the $125,000 contract payable reduction and accumulated amortization of $550,000.

 

Amortization expense on the VetStem license was $0 and $100,000 for the three months ended September 30, 2026 and 2025, respectively, and $100,000 and $200,000 for the six months ended September 30, 2026 and 2025, respectively. No amortization was recorded from July 1, 2026 to the July 24, 2026 termination. Under the termination agreement, the Company made a settlement payment of $75,000 to VetStem and returned all PrecisePRP™ inventory, which had a net carrying value of $120,046, and VetStem forgave accounts payable of $144,866, accrued royalties of $12,650 and the $125,000 milestone contract payment, totaling $282,516. As a result, the Company recognized a loss on termination of the license agreement of $237,530 for the three and six months ended September 30, 2026.

 

16

 

 

In September 2025, the Company signed an exclusive licensing agreement with Digital Landia Holding Corp to utilize their Artificial Intelligence (AI) under a B2B white-label model to target a bigger share of the veterinary industry within North America, the United Kingdom, and potentially other markets. The Company will market the software as its own brand and logo through exclusive Software-as-a-Service access rights. The exclusive licensing agreement is a ten-year agreement whereby the Company issued 1,000,000 shares of its common stock, with a fair value of $800,000, for the licensing fee. The fair value of the common stock issued as consideration was determined based on the quoted market price of the Company’s common stock on the measurement date. The licensing fee is recorded as an intangible asset and is amortized over one hundred twenty (120) months, the term of the agreement. The licensing agreement also has a royalty fee payment between 10% and 15%, commencing in the thirteenth month of the licensing agreement. No royalty expense was incurred for the three and six months ended September 30, 2026, and 2025, respectively.

 

Amortization expense was $20,000 and $5,111 for the three months ended September 30, 2026, and 2025, respectively. Amortization expense was $40,000 and $5,111 for the six months ended September 30, 2026 and 2025, respectively.

 

NOTE 7 – ACCRUED EXPENSES

 

The components of accrued expenses were as follows:

 

   September 30, 2026   March 31, 2026 
Contract payable  $-   $125,000 
Accrued payroll and related taxes   57,768    134,000 
Dividends payable   

125,000

    

125,000

 
Accrued expenses   4,216    69,713 
Total  $186,984   $453,713 

 

NOTE 8 – NOTES PAYABLE AND ACCRUED INTEREST TO RELATED PARTIES

 

In February and March 2026, the Company entered into two separate promissory notes totaling $320,000. The notes accrued interest at a rate of 6% per annum. The first promissory note was initiated on February 26, 2026, in the amount of $150,000 with a maturity date of February 26, 2027. The second promissory note was initiated on March 11, 2026, in the amount of $170,000 with a maturity date of March 11, 2027. These promissory notes are from significant stockholders and are related parties.

 

On June 22, 2026, the Company entered into another promissory note totaling $150,000 with a maturity date of June 22, 2027, with an accrued interest rate of 6% per annum. This promissory note is from a significant stockholder and is a related party.

 

In July 2026, the Company entered into two separate promissory notes totaling $230,000. The first promissory note was initiated on July 9, 2026, in the amount of $100,000 with a maturity date of January 9, 2027, with an accrued interest rate of 10% per annum. The second promissory note was initiated on July 27, 2026, in the amount of $130,000 with a maturity date of July 27, 2027, with an accrued interest rate of 6% per annum. These promissory notes are from significant stockholders and are related parties.

 

In August 2026, the Company entered into three separate promissory notes totaling $325,000. The first promissory note was initiated on August 10, 2026, in the amount of $150,000 with a maturity date of February 10, 2027, with an accrued interest rate of 10% per annum. The second promissory note was initiated on August 10, 2026, in the amount of $50,000 with a maturity date of November 10, 2026, with an accrued interest rate of 10% per annum. This $50,000 promissory note maturity date was extended to January 10, 2027. The third promissory note was initiated on August 26, 2026, in the amount of $125,000 with a maturity date of August 26, 2027, with an accrued interest rate of 6% per annum. These promissory notes are from significant stockholders and are related parties.

 

In September 2026, the Company entered into three separate promissory notes totaling $250,000. The first promissory note was initiated on September 11, 2026, in the amount of $100,000 with a maturity date of September 11, 2027, with an accrued interest rate of 10% per annum. The second promissory note was initiated on September 22, 2026, in the amount of $100,000 with a maturity date of December 22, 2026, with an accrued interest rate of 10% per annum. The third promissory note was initiated on September 23, 2026, in the amount of $50,000 with a maturity date of March 23, 2027, with an accrued interest rate of 10% per annum. These promissory notes are from significant stockholders and are related parties.

 

Accrued interest on all notes at September 30, 2026, was $21,850.

 

As of September 30, 2026, total non-convertible notes payable, including accrued interest, were $1,296,850, consisting of $1,296,850 classified as current liability and $0 classified as long-term liabilities. As of March 31, 2026, the balance totaled $321,447, consisting of $321,447 classified as current liability and $0 classified as long-term liabilities within other liabilities.

 

Total interest expense for all Notes for the three months ended September 30, 2026 and 2025 is $15,394 and $1,946, respectively. Total interest expense for all Notes for the six months ended September 30, 2026 and 2025 is $20,403 and $11,220.

 

17

 

 

NOTE 9 – CONVERTIBLE NOTES PAYABLE AND ACCRUED INTEREST

 

On March 8, 2024, the Company entered into a convertible promissory note for $150,000. The note accrued interest at a rate of 10% per annum. The principal and accrued interest were due in April 2024. The holder of the note had the option to convert the principal and accrued interest into shares of the Company’s common stock at a conversion rate of $0.70 per share. On April 10, 2024, the company entered into another promissory note for an additional $150,000 whereby the new principal balance was $300,000 with the same terms. On April 29, 2024, the noteholder converted the $300,000 principal balance, along with $1,558 of accrued interest into 430,798 common shares.

 

From September 1, 2024 through March 31, 2025, the Company borrowed $1,715,000 in convertible promissory notes with an interest rate of 10% per annum. Certain of these notes had conversion terms of the lesser of our stock trading price or $0.50 per share, and the remaining notes had fixed conversion prices. On June 10, 2025, the Company entered into a promissory note for $160,000 at a rate of 10% per annum and a maturity date of December 31, 2025. This note included the issuance of 75,000 warrants, with a two-year term and a strike price of $0.75 per share and had a fair value of $23,649. The Company used the Black-Scholes option pricing model to calculate the warrant fair value, with the following assumptions: no dividend yield, expected volatility of 119.3%, risk free interest rate of 3.72%, and expected option life of 2.0 years. The fair value is required to be recorded as a debt discount and amortized to interest expense over the term of the note. The $23,649 debt discount was fully amortized to interest expense by September 30, 2025, when the note was converted into common stock.

 

On September 30, 2025, the Company repaid a $25,000 convertible promissory note, dated December 20, 2024, and accrued interest of $2,334.

 

On September 30, 2025, the Company issued 3,669,806 shares of common stock in settlement of convertible notes with principal of $1,850,000 and accrued interest of $168,154 (total $2,018,154), at conversion prices of $0.50 to $0.75 per share.

 

The total convertible notes payable, including accrued interest, for these convertible notes is $0 at September 30, 2026 and March 31, 2026.

 

Interest expense, including amortization of debt discount, on these convertible notes payable for the three months ending September 30, 2026 and 2025 is $0 and $69,622, respectively. Interest expense, including amortization of debt discount, on these convertible notes payable for the six months ending September 30, 2026 and 2025 is $0 and $113,467.

 

June 30, 2025 Amendment to Convertible Notes and Extinguishment Accounting

 

On June 30, 2025, the Company and the holders of the notes with variable conversion terms entered into an amendment to fix the conversion price at $0.50 per share, eliminate the variable pricing feature, and change their maturity dates to September 30, 2025. As a result of the amendment, the conversion feature no longer required separate derivative liability accounting under ASC 815. Under ASC 470-20, as amended by ASU 2020-06, the conversion feature was not separately recognized from the debt host.

 

The Company evaluated the amendment under ASC 470-50, Modifications and Extinguishments, and concluded that the amendment represented a substantial modification due to the elimination of the variable conversion feature and the resulting change in economic substance. Accordingly, the Company accounted for the amendment as an extinguishment of the existing notes and the issuance of new convertible notes. Because substantially all of the amended notes were held by significant stockholders who are related parties (Note 10), the extinguishment was accounted for as a capital transaction, with no gain or loss recognized.

 

The new notes had a principal amount of $1,215,000, and the $768,493 derivative liability was eliminated to additional paid-in capital. In accordance with ASC 470-20, as amended by ASU 2020-06, the conversion feature was not separately recognized as a beneficial conversion feature, and no related debt discount was recorded.

 

The accounting impact of the amendment is summarized as follows, as of June 30, 2025:

 

Description  Amount 
Principal amount of extinguished notes  $1,215,000 
New notes issued, principal amount  $1,215,000 
Derivative liability eliminated to additional paid-in capital  $768,493 

 

18

 

 

The amended convertible notes were matured and were fully converted on September 30, 2025.

 

Convertible Notes Issued with Warrants

 

On February 14, 2025, a total of 250,000 warrants were issued for two Notes totaling $500,000. The warrants have a three-year term with an exercise strike price of $0.90 per share. The warrants were evaluated under ASC 480 and ASC 815 and determined to be equity-classified instruments. The fair value of the warrants at inception was recorded at a discount to the carrying value of the associated notes and is being amortized to interest expense over the term of the notes using the effective interest method. The fair value at issuance was estimated using the binomial option pricing model with the following inputs: closing stock price of $0.74, strike price of $0.90, 3-year term, volatility rate of 113.7%, risk-free rate of 4.26%, and dividend yield of zero. The fair value of the warrants at inception was $98,684 and were being amortized over the thirty-six-month term. On September 30, 2025, the convertible notes were converted into common stock and the unamortized remaining balance of the debt discount of $90,219 was fully amortized. Interest expense related to the amortization of the debt discounts associated with warrants was $0 and $107,034 for the three months ending September 30, 2026 and 2025, respectively. Interest expense related to the amortization of the debt discounts associated with warrants was $0 and $117,280 for the six months ended September 30, 2026 and 2025, respectively.

 

Fair Value Allocation of Proceeds from Convertible Notes

 

When convertible notes are issued with warrants, and no derivative liability is present, the proceeds are allocated between the debt and the warrants based on their relative fair values at issuance. When convertible notes are issued with both detachable warrants and embedded derivative liabilities, the proceeds are allocated using a sequential approach: first to the derivative liability at fair value, then to the warrants at fair value, and the residual amount to the debt host. For convertible notes that include only an embedded derivative liability and no warrants, the proceeds are allocated first to the derivative liability at fair value, with the residual amount allocated to the debt host.

 

Derivative Liabilities – Variable Conversion Features

 

The Company had $1,215,000 of convertible notes that contained derivative features and evaluated the terms of these convertible notes and determined that certain embedded conversion features were not indexed to the Company’s own stock due to variable conversion price provisions. Accordingly, the embedded conversion features were bifurcated from the host debt instruments and accounted for as derivative liabilities in accordance with ASC 815, Derivatives and Hedging. All of the convertible notes contained derivatives, with similar conversion terms.

 

The derivative liabilities were measured at fair value on a recurring basis and classified as Level 3 within the fair value hierarchy due to the use of significant unobservable inputs. The initial fair value of the embedded derivatives was recorded as a debt discount with a corresponding derivative liability and was amortized to interest expense over the contractual term of the related notes using the effective interest method.

 

The fair value of the derivative liabilities was estimated using a binomial option pricing model. The significant assumptions utilized in determining the fair value of the derivative liabilities, based on the weighted-average of the convertible notes, were as follows:

 

Input  Inception   March 31, 2025   June 30, 2025 
Closing stock price  $0.41   $0.60   $1.10 
Conversion price  $0.50   $0.50   $0.50 
Remaining contractual term (years)   3.0    2.75    2.25 
Expected volatility   135.1%   103.5%   82.1%
Risk-free interest rate   4.16%   4.08%   3.85%
Dividend yield   0.0%   0.0%   0.0%

 

19

 

 

The following table summarizes activity in the Company’s derivative liabilities:

 

   Amount 
Fair value at inception  $341,576 
Change in fair value during fiscal 2025   106,513 
Fair value at March 31, 2025   448,089 
Change in fair value through June 30, 2025   320,404 
Fair value at amendment in June 30, 2025   768,493 
Derivative liability eliminated to additional paid-in capital upon amendment   (768,493)
Fair value at September 30, 2026  $0 

 

The Company recognized an unrealized loss of $320,404 related to changes in the fair value of derivative liabilities for the six months ended September 30, 2025.

 

On September 30, 2025, all outstanding convertible notes were converted into shares of the Company’s common stock. No gain or loss was recognized upon conversion. As a result, the Company had no outstanding derivative liabilities as of September 30, 2026 and March 31, 2026.

 

Interest expense related to the amortization of debt discounts associated with derivative liabilities was $0 for the three months ending September 30, 2026 and 2025. Interest expense related to the amortization of debt discounts associated with derivative liabilities was $0 and $56,013 for the six months ending September 30, 2026 and 2025, respectively.

 

NOTE 10 – RELATED PARTY TRANSACTIONS

 

The Company enters into transactions with related parties in the normal course of business. These include entities controlled by members of its Board of Directors, its executive officers and its principal stockholders. Material related party transactions and balances are as follows.

 

Notes Payable – Significant Stockholders

 

From February 26, 2026 through the quarter ending September 30, 2026, the Company issued eleven unsecured, nonconvertible promissory notes in the aggregate principal amount of $1,275,000 to three significant stockholders: Alexander Nazarenko, Alan Sarroff and Stanley Cruden. The notes bear interest at rates of 6% to 10% per year with maturity dates between November 10, 2026 and September 11, 2027. The proceeds were used for working capital. The principal balance was $320,000 at March 31, 2026 and $1,275,000 at September 30, 2026. Accrued interest owed to these shareholders was $21,850 at September 30, 2026, and related interest expense was $15,394 and $20,403 for the three and six months ended September 30, 2026.

 

From October 13, 2026 to November 3, 2026, the Company issued four unsecured, nonconvertible promissory notes in the aggregate principal amount of $360,000 to three significant stockholders: Alexander Nazarenko, Alan Sarroff and Stanley Cruden. The notes bear interest rate of 10% per year with maturity dates between November 23, 2026 and May 3, 2027. The proceeds were used for working capital.

 

Convertible Notes – Significant Stockholders

 

The convertible notes outstanding during the six months ended September 30, 2025 were held principally by significant stockholders. Certain of the notes were amended on June 30, 2025 (Note 9), and on September 30, 2025 the holders converted $1,850,000 of principal and $168,154 of accrued interest into 3,669,806 shares of common stock.

 

Consulting Services to Board Members

 

The Company has consulting agreements with two members of our Board of Directors, Michael Handley and Dr. Jaime Pickett, for regulatory, product development and acquisition advisory services, effective September 22, 2026. As of September 30, 2026, the Company owed Mr. Handley and Dr. Pickett a total of $22,792, consisting of consulting fees and unreimbursed expenses.

 

Equity Transactions with Officers

 

In September 2026, the Company sold a total of 62,500 shares of our common stock to our Chief Executive Officer and our Chief Financial Officer with a share purchase price of $0.80 per share for total proceeds of $50,000. The Company also issued three-year warrants to purchase up to 62,500 shares of our common stock with a strike price of $1.10 per share as part of the subscription offering.

 

Board of Directors Accrued Compensation Conversion

 

A former director converted $8,587 of accrued board compensation into 12,628 shares of our common stock. Diane Levitan resigned from our Board of Directors effective September 22, 2026.

 

NOTE 11 – RETIREMENT PLAN

 

In February 2021, the Company established a defined contribution retirement plan under Section 401(k) of the Internal Revenue Code for eligible employees. Participants may contribute a portion of their eligible compensation to the plan, subject to applicable statutory limitations. The Company may make discretionary employer contributions. Employer contribution expense was $17,544 and $17,796 for the three months ended September 30, 2026 and 2025, respectively. Employer contribution expense was $35,966 and $33,675 for the six months ended September 30, 2026 and 2025, respectively.

 

20

 

 

NOTE 12 – COMMITMENTS AND CONTINGENCIES

 

The Company accounts for contingencies in accordance with ASC 450, Contingencies. A liability is recorded when it is probable that a loss has been incurred and the amount can be reasonably estimated. If a loss is reasonably possible but not probable, or if the amount cannot be estimated, the nature of the contingency and an estimate of the possible loss, if determinable, is disclosed. Remote contingencies are generally not disclosed unless related to guarantee.

 

Lease Obligations

 

The Company leases property and equipment under operating leases, typically with terms greater than 12 months, and determine if an arrangement contains a lease at inception. In general, an arrangement contains a lease if there is an identified asset and we have the right to direct the use of and obtain substantially all of the economic benefit from the use of the identified asset. We record an operating lease liability at the present value of lease payments over the lease term on the commencement date. The related right of use (‘‘ROU”) operating lease asset reflects rental escalation clauses, as well as renewal options and/or termination options. The exercise of lease renewal and/or termination options is at our discretion and is included in the determination of the lease term and lease payment obligations when it is deemed reasonably certain that the option will be exercised. When available, we use the rate implicit in the lease to discount lease payments to present value; however, certain leases do not provide a readily determinable implicit rate. Therefore, we must estimate our incremental borrowing rate to discount the lease payments based on information available at lease commencement.

 

The Company classifies its leases as buildings, vehicles or computer and office equipment and do not separate lease and non-lease components of contracts for any of the aforementioned classifications. In accordance with applicable guidance, we do not record leases with terms that are less than one year on the Consolidated Balance Sheets.

 

None of our lease agreements contain material restrictive covenants or residual value guarantees.

 

Buildings

 

The Company entered into an eighty-four month lease for 3,577 square feet of newly constructed office, laboratory, and warehouse space located in Edina, Minnesota in May 2017, which was renewed for an additional thirty months resulting in the lease expiration in November 2026. The base rent has annual increases of 2% and the Company is responsible for its proportional share of common space expenses, property taxes, and building insurance. This lease is terminable by the landlord if damage causes the property to no longer be utilized as an integrated whole and by the Company if damage causes the facility to be unusable for a period of 45 days. In January 2020, the Company entered into a lease amendment to extend the lease term through November of 2026 in exchange for receipt of a loan of $42,500 recorded to note payable. In July 2026, the Company entered into another lease amendment to extend the lease term twenty-four months through November 14, 2028. The monthly base rent as of September 30, 2026, and March 31, 2026, was $2,434.

 

The Company entered into a sixty-three month lease for 2,400 square feet of office space located in Edina, Minnesota in January 2022. This lease will expire in March 2027. The base rent has annual increases of 2.5% and the Company is responsible for its proportional share of common space expenses, property taxes, and building insurance. The monthly base rent as of September 30, 2026, and March 31, 2026, was $2,950.

 

On January 10, 2023, the Company entered into a new lease agreement for approximately 14,000 square feet of production and warehouse space with a commencement date of April 1, 2023, which is when the control and right of use for this asset took place. The initial monthly base rent is $8,420 and has annual increases of 2.5%. The Company is also responsible for its proportional share of common space expenses, property taxes, and building insurance. The lease was terminated on June 30, 2025.

 

Lease Termination

 

Effective June 30, 2025, the Company terminated its ten-year lease for approximately 14,000 square feet of production and warehouse space. In connection with the termination, the Company agreed to reimburse the landlord for certain unamortized leasing costs, rent abatements, tenant improvements, legal and management fees, costs associated with releasing a mechanical lien, and an amount equal to six months of base rent, common area maintenance charges and real estate taxes attributable to approximately 3,794 square feet of unrented office space.

 

Upon termination of the lease, the Company derecognized the related operating lease right-of-use asset of $843,783 and operating lease liability of $843,783 and recognized a loss on lease termination of $149,125. The Company also incurred lease termination and related costs of $0 and $314,768 for the three and six months ended September 30, 2025, respectively. No additional lease termination costs were recognized during the three and six months ended September 30, 2026. 

 

21

 

 

The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities as of September 30, 2026:

 

     
2027   35,978 
2028   40,149 
2029   27,557 
2030   - 
Thereafter   - 
Total  $103,684 
Less: amount representing interest   (514)
Total  $103,170 

 

In compliance with ASC 842 Leases, the Company recognized, based on the extended lease terms to November 14, 2028, and March 2027, a weighted average incremental borrowing rate of 4.69%, an operating lease right-of-use assets for approximately $103,170 and corresponding and equal operating lease liabilities for the leases. As of September 30, 2026, the present value of future base rent lease payments based on the remaining lease term is approximately two years, are as follows:

 

     
Present value of future base rent lease payments  $103,170 
Base rent payments included in prepaid expenses   - 
Present value of future base rent lease payments – net  $103,170 

 

As of September 30, 2026 and March 31, 2026, operating lease right-of-use assets and operating lease liabilities were classified as follows:

 

   September 30, 2026   March 31, 2026 
Operating lease right-of-use asset  $103,170   $54,711 
Total operating lease assets   103,170    54,711 
           
Operating lease current liability   55,446    54,711 
Operating lease non-current liability   47,724    - 
Total operating lease liabilities  $103,170   $54,711 

 

Employment Agreements

 

The Company has employment agreements with its executive officers. As of September 30, 2026, these agreements contain severance benefits ranging from one month to six months if terminated without cause.

 

Legal Proceedings

 

From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business. In June 2026, a former employee filed a whistleblower retaliation complaint with the Occupational Safety and Health Administration (OSHA) under Sarbanes-Oxley Act (SOX), 18 U.S.C. § 1514A. The claimant alleges they were wrongfully terminated after reporting alleged governance and honesty in shareholder relations.

 

The Company is cooperating with OSHA’s ongoing investigation, denies all allegations and intends to vigorously defend against these allegations. At this preliminary stage, the outcome is uncertain. Although the Company cannot predict the ultimate outcome of this matter, based on currently available information, management cannot estimate the possible loss or range of loss because such amount cannot be reasonably estimated. Management does not believe that the ultimate resolution of this matter will have a material adverse effect on the Company’s consolidated financial position, results of operations, or cash flows.

 

22

 

 

NOTE 13 – GOING CONCERN

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.

 

The Company incurred a net loss of $3,560,419 for the six months ended September 30, 2026, had net cash used in operating activities of $1,912,820 for the same period, and has an accumulated deficit of $105,122,925 on September 30, 2026. The Company had a working capital deficit of $1,559,817; a stockholders’ deficit of ($159,093); cash on hand at September 30, 2026 of $16,287 and $1,275,000 of non-convertible notes, in addition to $360,000 of new notes issued in October and November 2026, all maturing within twelve months. Also, the Company initiated a $2,000,000 private equity offering in late October, to raise new capital for the company. As of the date of this Form 10-Q filing, no subscription agreements have been signed, and no proceeds have been received by the Company.

 

These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these consolidated financial statements are issued.

 

Management’s plans to address these conditions include continuing efforts to improve operating results, reduce operating costs, increase revenues, and obtain additional capital through debt and/or equity financing arrangements. The Company has historically relied on external financing to fund its operations and expects to continue to seek additional financing as needed.

 

There can be no assurance that the Company will be successful in achieving profitable operations, securing additional financing on acceptable terms, or successfully implementing its business plan. Accordingly, management has concluded that substantial doubt about the Company’s ability to continue as a going concern is not alleviated.

 

The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

NOTE 14 – STOCKHOLDERS’ EQUITY

 

Equity Incentive Plan

 

On July 10, 2020, our Board of Directors unanimously approved the PetVivo Holdings, Inc “2020 Equity Incentive Plan” (the “2020 Plan”), which authorized the issuance of up to 1,000,000 shares of our common stock as awards under the 2020 Plan, subject to approval by our stockholders at the Annual Meeting of Stockholders held on September 22, 2020, when it was approved by our stockholders and became effective. On October 14, 2022, the stockholders of the Company approved the PetVivo Holdings, Inc. Amended and Restated 2020 Equity Incentive Plan (the “Amended Plan”), which increased the number of shares of the Company’s common stock which may be granted under the Amended Plan from 1,000,000 to 3,000,000. Unless sooner terminated by the Board, the Amended Plan will terminate at midnight on July 10, 2030.

 

The Amended Plan is administered by the Compensation Committee of our Board of Directors (the “Committee”), which has full power and authority to determine when and to whom awards will be granted, and the type, amount, form of payment, any deferral payment, and other terms and conditions of each award. Subject to provisions of the Amended Plan, the Committee may amend or waive the terms and conditions, or accelerate the exercisability, of an outstanding award. The Committee also has the authority to interpret and establish rules and regulations for the administration of the Amended Plan. In addition, the Board of Directors may also exercise the powers of the Committee.

 

The number of shares available to grant under the Amended Plan was 0 shares at September 30, 2026.

 

Sale of Common Stock

 

In March 2026, the Company entered into a private placement with an over ten percent shareholder, pursuant to which it agreed to sell 1,250,000 shares of restricted common stock at a purchase price of $0.80 per share for aggregate proceeds of $1,000,000. As of March 31, 2026, the Company had received $400,000 of the purchase price and recorded the remaining $600,000 as a subscription receivable pursuant to an enforceable subscription agreement. The transaction was recorded as common stock to be issued and a subscription receivable at March 31, 2026. The remaining $600,000 was received on April 20, 2026.

 

In June 2026, the Company entered into a private placement with an over ten percent shareholder for the sale of up to 1,875,000 shares of restricted common stock at $0.80 per share (up to $1,500,000). The investor purchased 187,500 shares for $150,000. The remaining $1,350,000 is a purchase option that the investor is not obligated to exercise, and it has been extended to December 15, 2026. As of the date of this Form 10-Q filing, no additional proceeds have been received.

 

In September 2026, the Company entered into two separate private placement offerings with its Chief Financial Officer and its Chief Executive Officer, both related parties, pursuant to which it agreed to sell 62,500 shares of restricted common stock at a purchase price of $0.80 per share for aggregate proceeds of $50,000.

 

Preferred Stock

 

On March 26, 2025, the Company entered into a Subscription Agreement to receive 5,000,000 shares of Series B Preferred Stock. The Company initially received $600,000 of proceeds on March 26, 2025, with the investor receiving an option to invest the remaining $4,400,000 pursuant to the same terms and conditions, which was fully received and funded on June 24, 2025.

 

23

 

 

Series B Preferred Stock is entitled to receive a specific dividend in an annual amount equal to Ten Percent (10%) of the total amount paid to secure the Series B Convertible Preferred Stock. The dividend shall be paid to the holder by the Company in quarterly payments of Common Stock. The amount of shares pursuant to the dividend shall be calculated by dividing the total quarterly dividend payment by the greater of i) the volume weighted average price of the common stock for the prior trading ten (10) day period from the date the quarterly dividend is owed, or ii) fifty cents ($0.50). Also, non-cumulative dividends may be paid when, and if declared by the Company’s board of directors. Total dividends declared for the six months ended September 30, 2026 and for the full fiscal year ending March 31, 2026 were $250,000 and $403,603, respectively.

 

Upon any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, no distributions of available funds and assets will be made to the holders of Common Stock until the holders of Series B Preferred Stock receive a per share amount equal to the original issue price.

 

Common Stock

 

During the six months ended September 30, 2026, the Company issued 2,279,726 shares of common stock as follows:

 

i) 937,500 shares in April 2026 and June 2026 in connection with the sale of stock at a price of $0.80 per share in exchange for proceeds of $750,000 recorded against common stock.
ii) 200,000 shares in June 2026 to a service provider for consulting services fair valued based on the market price on the date of grant of $160,000. The Company will expense these shares on a monthly basis through September 2026.
iii) 368,152 shares to employees in April 2026 to June 2026 for performance services fair valued at $288,225 based on the market price at date of grant and expensed in the same period that they were issued.
iv) 176,174 shares in April 2026, fair valued at $125,000, for conversion of $125,000 of accrued dividends on Series B Preferred Stock.
v) 62,500 shares in April 2026 to the board of directors for advisory services and compensation fair valued at $42,000 based on the market price date of grant.
vi) 242,157 shares to employees in July 2026 to September 2026 for performance services fair valued at $190,050 based on the market price at date of grant and expensed in the same period that they were issued.
vii) 156,250 shares in July 2026, fair valued at $125,000, for the conversion of $125,000 of accrued dividends on Series B Preferred Stock.
viii) 50,000 shares in July 2026 to the board of directors for advisory services and compensation fair valued at $42,000 based on the market price date of grant.
ix) 12,628 shares in September 2026 to a board member for conversion of accrued board compensation fair valued at $8,587 based on a 10-day VWAP from the date of grant.
x) 11,865 shares in September 2026 to a board member for the conversion of 35,954 stock options valued at $8,068 based on a 10-day VWAP from the date of grant.
xi) 62,500 shares in September 2026 in connection with the sale of stock at a price of $0.80 per share in exchange for proceeds of $50,000 recorded against common stock.

 

The Company has issued shares of common stock to providers of investor relations services. The value of these shares are reported as a prepaid expense and are amortized to expense over the contractual life of the respective consulting agreements. The amortization of previously prepaid investor relations stock issued for services was $156,414 and $15,750 for the three months ended September 30, 2026, and 2025, respectively. The amortization of previously prepaid investor relations stock issued for services was $207,881 and $31,500 for the six months ended September 30, 2026, and 2025, respectively.

 

Stock Options

 

Stock options issued to employees and directors typically vest over three years (one year for directors) and have a contractual term of seven years. Stock-based compensation expense for stock options was $0 and $5,508 for the three months ended September 30, 2026, and 2025, respectively and $0 and $13,772 for the six months ended September 30, 2026, and 2025, respectively. As of September 30, 2026, all outstanding options were fully vested; therefore, there was no unrecognized stock option expense.

 

24

 

 

No stock options were granted during the six months ended September 30, 2026; therefore, no weighted-average assumptions are presented for the period.

 

Stock option activity for the six months ended September 30, 2026 is as follows:

 

   Options
Outstanding
   Weighted-
Average
Exercise
Price Per
Share
  

Weighted-

Average

Remaining

Contractual

Life

  

Aggregate

Intrinsic

Value (1)

 
Balance at March 31, 2026   35,954   $1.06    0.75 years   $       - 
Converted to common stock   (35,954)   1.06    0.75 years    - 
Granted   -    -           
Cancelled   -    -           
Balance at September 30, 2026   -   $-    -   $- 
                     
Options exercisable at September 30, 2026   -   $-    -   $- 

 

(1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price of $0.80 for the Company’s common stock on September 30, 2026 and the closing stock price of $0.70 for the Company’s common stock on March 31, 2026.

 

Warrants

 

 During the six months ended September 30, 2026, the Company issued warrants to purchase an aggregate of 212,500 shares  of common stock in connection with consulting and subscription agreements with a grant-date fair value of $64,303. Expense related to these warrants was $4,481 and $6,531 for the three and six months ended September 30, 2026, respectively. These warrants have a term of 3 years. The exercise strike price ranges from $0.75 to $1.10 per share.

 

The fair value of the warrants issued was estimated using the Black-Scholes valuation model with the following assumptions:

 

   Six Months Ended   Year Ended 
   September 30, 2026   March 31, 2026 
Stock price on valuation date  $0.68 - $0.80    $0.70 - $1.15  
Exercise price  $0.75 - $1.10    $0.75 - $1.10  
Term (years)   3.0    2.0 – 3.0  
Volatility   105.3 – 105.7%   106.1 – 119.3%
Risk-free rate   3.73 – 4.49%   3.72% – 3.81%

 

A summary of warrant activity for six months ended September 30, 2026 is as follows:

 

   Number of

Warrants
   Weighted-
Average
Exercise
Price
   Weighted
Average
Remaining
Contractual
Term
(in years)
   Weighted-
Average
Exercisable
Price
 
                 
Outstanding, March 31, 2026   15,999,081   $2.26    1.58   $2.26 
Granted and issued   212,500    0.85    3.00    0.85 
Exercised   -    -    -    - 
Expired   (4,638,558)   4.38    0.08    - 
Outstanding, September 30, 2026   11,573,023   $1.38    1.27   $1.38 

 

25

 

 

Stock-based compensation expense for warrants was $134,564 and $92,728 for the three months ended September 30, 2026, and 2025, respectively, and $266,697 and $166,752 for the six months ended September 30, 2026 and 2025, respectively. At September 30, 2026, there was $1,098,562 of future unrecognized warrant expense, to be expensed quarterly over the remaining life of the warrants, over the next 35.5 months.

 

NOTE 15 – SEGMENT REPORTING

 

The Company manages the business activities on a consolidated basis and operates in one reportable segment. The Company’s reportable segment is an emerging biomedical device company focused on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for animals. The segment is animal health products. As the Company has one reportable segment, sales and marketing, research and development, including clinical trial expenses and general and administrative expenses are equal to consolidated results. Financial results for the Company’s reportable segment have been prepared using a management approach, which is consistent with the basis and manner in which financial information is evaluated by the Company’s Chief Operating Decision Maker (“CODM”) in allocating resources and in assessing performance. The Company’s CODM is the Chief Executive Officer. The measurement of segment profit or loss that the CODM uses to evaluate the performance of the Company’s segment is net operating loss attributable to animal health. The CODM reviews financial budgets and actual results to assess performance and allocate resources, and makes strategic decisions related to headcount and related expenses, stock compensation, research and development/clinical trial expense and other expenditures on a consolidated basis.

 

   2026   2025   2026   2025 
  

For the Three Months Ended

September 30,

  

For the Six Months Ended

September 30,

 
   2026   2025   2026   2025 
                 
NET REVENUE  $212,806   $303,284   $550,377   $600,784 
Cost of Sales   16,731    83,226    130,985    194,000 
Gross Profit   196,075    220,058    419,392    406,784 
OPERATING EXPENSES                    
Sales and marketing   645,933    787,262    1,277,238    1,408,974 
Loss on termination of license agreement   

237,530

    -    

237,530

    - 
Research and development   322,296    261,433    555,714    601,946 
General and administrative   921,321    1,236,730    1,888,764    2,305,547 
Total operating expenses   2,127,080    2,285,425    3,959,246    4,316,467 
NET OPERATING LOSS  $(1,931,005)  $(2,065,367)  $(3,539,854)  $(3,909,683)

Loss on lease termination

   -    -    -    (149,125)

Unrealized loss on change in derivative liabilities

   -    -    -    (320,404)

Other Income

   -    -    -    111,517 

Interest Income

   -    -    -    13,099 

Interest Expense

   (15,526)   (179,183)   (20,565)   (300,991)

TOTAL OTHER INCOME (EXPENSE)

   (15,526)   (179,183)   (20,565)   (645,904)

NET LOSS

  $(1,946,531)  $(2,244,550)  $(3,560,419)  $(4,555,587)

 

NOTE 16 – INVESTMENTS IN EQUITY SECURITIES

 

In March 2025, the Company signed a strategic alliance agreement with Digital Landia Holding Corp, a pioneer in Agentic AI solutions for a Pet AI platform. Under the agreement, PetVivo exchanged $150,000 in 230,770 shares of restricted common stock for an approximate 2% equity stake in Digital Landia, thereby becoming the Platinum Sponsor of the Pet AI community. Having an only 2% equity stake in Digital Landia, management does not consider the investment in Digital Landia is a related party. PetVivo will also receive economic benefits from 3 million Digital Landia tokens expected to be launched upon proper market conditions.

 

As an exclusive advertiser for lameness and joint affliction medical device products, as well as regenerative therapeutic products, PetVivo’s SPRYNG® with OsteoCushion® Technology product will be promoted to users when the AI detects joint related afflictions or other degenerative afflictions in pets. Further with the strategic alliance agreement, the Company issued 1,000,000 warrants to Digital Landia fair valued at $35,197.

 

The Company holds equity investments in Digital Landia Holding Corp, a privately held entity that does not have readily determinable fair values for its common stock. The Company elected the measurement alternative for eligible non-marketable equity securities under ASC 321-10-35-2. These investments are carried at historical cost and adjusted upward or downward for observable price changes in orderly transactions for the identical or similar investment of the same issuer, less any impairment. As of the date of this report, as of September 30, 2026, the Company continues to use the $150,000 historical cost of the PetVivo shares issued in exchange for $150,000 of the Digital Landia shares. There have been no observable price changes or impairments, so the carrying amount of $150,000 remains at its historical cost.

 

NOTE 17 – INCOME TAXES

 

No income tax benefit has been recorded for the periods ended September 30, 2026, and 2025, as the Company has incurred operating losses and maintains a full valuation allowance against its net deferred tax assets.

 

Interim Effective Tax Rate: The Company’s effective tax rate was 0.0% for the six months ended September 30, 2026 and 2025, compared with the U.S. federal statutory income tax rate of 21.0%. The difference between the Company’s effective tax rate and the U.S. federal statutory rate was primarily attributable to the valuation allowance recorded against the Company’s deferred tax assets.

 

Discrete Items: There have been no discrete items in the period ending September 30, 2026.

 

Uncertain Tax Positions: There have been no material changes to the total amount of unrecognized tax benefits or our position on uncertain tax positions since March 31, 2026.

 

NOTE 18 – SUBSEQUENT EVENTS

 

In accordance with ASC 855, the information below are subsequent transactions from the end of the September 30, 2026 reporting period to the date of this filing on November 16, 2026.

 

In October 2026, the Company issued 156,250 shares of restricted stock for the conversion of accrued dividends on Series B Preferred Stock valued at $125,000.

 

On October 6, 2026, OTC Markets downgraded our listing from OTCQX (Best Market) to OTCQB (Venture Market), due to OTCQX maintenance listing requirements whereby we have not met the $2 million net tangible assets threshold under Rule 3a51-1 of the Exchange Act.

 

In October 2026, the Company issued 43,038 shares of restricted stock to two board members for the conversion of accrued board compensation valued at market on the date of grant of $29,266.

 

From October 13 to November 3, 2026, the Company received proceeds of $360,000 on the promissory notes with a maturity date between November 23, 2026 and May 3, 2027, and an accrued interest rate of 10% per annum with no conversion provisions. These promissory notes are from significant stockholders and are related parties.

 

In October, 2026, the Company issued an aggregate of 57,500 shares of restricted common stock to five members of the board of directors and an employee for compensation for their quarterly service from July 1 to September 30, 2026, valued at $46,000 based on the closing stock price on September 30, 2026.

 

On October 12, 2026, the Company issued 150,000 restricted shares to certain employees as compensation for past performance, valued at $102,000 based on the closing price on the grant date, which will be expensed in the quarter ending December 31, 2026.

 

In late October 2026, the Company initiated a private equity offering of up to $2,000,000 to raise new capital. As of the date of this Form 10-Q filing, no subscription agreements have been signed, and no proceeds have been received by the Company.

 

On October 29, 2026, the Company amended the $50,000 promissory note dated August 10, 2026 to extend the maturity date from November 10, 2026 to January 10, 2027.

 

26

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

GENERAL

 

PetVivo Holdings, Inc. (the “Company,” “PetVivo,” “we” or “us) is an emerging biomedical device company focused on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for animals. The Company has a pipeline of seventeen products for the treatment of animals and humans. A portfolio of ten issued patents (consisting of six U.S. patents and four foreign patents), two U.S. patent applications, and six proprietary trade secrets protects the Company’s biomaterials, products, production processes and methods of use. The Company began commercialization of its lead product Spryng® with OsteoCushion® Technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses, in the second quarter of its fiscal year ended March 31, 2022.

 

In August 2021, we received net proceeds of approximately $9.7 million in a registered public offering (“Public Offering”) of 2.5 million units at a public offering price of $4.50 per unit. Each unit consisted of one share of our common stock and one warrant to purchase one share of our common stock at an exercise price of $5.625 per share. The shares of common stock and warrants were transferable separately immediately upon issuance. In connection with the Public Offering, the Company’s common stock and warrants were registered under Section 12(b) of the Exchange Act and began trading on The Nasdaq Capital Market, LLC under the symbol “PETV”. Presently, the Company is trading on the OTC Markets Group, under the OTCQB (Venture Market) tier under the same symbol “PETV”.

 

The Company was incorporated in March 2009 under Nevada law. The Company operates as one segment from its corporate headquarters in Edina, Minnesota.

 

CURRENT BUSINESS OPERATIONS

 

The Company is primarily engaged in the business of commercializing and licensing products in the veterinary market to treat and/or manage afflictions of companion animals such as dogs and horses. Most of our technology was developed for human biomedical applications, and we intend to leverage the investments already expended in their development to commercialize treatments for horses and companion animals in a capital and time-efficient way.

 

Many of the Company’s products are derived from proprietary biomaterials that simulate a body’s cellular tissue by virtue of their reliance upon natural protein and carbohydrate compositions which incorporate such “tissue building blocks” as collagen, elastin, and proteoglycans such as heparin. Since these are naturally-occurring in the body, we believe they have an enhanced biocompatibility with living tissues compared to synthetic biomaterials such as those based upon alpha-hydroxy polymers (e.g PLA, PLGA, and the like), polyacrylamides, and other “natural” biomaterials that may lack the multiple proteins incorporated into our biomaterials. These proprietary protein-based biomaterials that are similar to the body’s tissue thus allowing integration and tissue repair in long-term implantation in certain applications.

 

Our initial product, Spryng® is a veterinary medical device designed and engineered to provide a bio-integrative scaffold in the affected joint, promoting restoration of proper joint mechanics. Spryng® is an intra-articular injectable product of biocompatible and insoluble particles that are slippery, wet-permeable, durable, and resilient to enhance the force cushioning function of the synovial fluid and cartilage. The particles mimic natural cartilage in composition, structure, and hydration. Multiple joints can be treated simultaneously. Our particles are comprised of naturally derived collagen, elastin, and a glycosaminoglycan (i.e. heparin); such particles mimic the composition and mechanical properties of extracellular matrix and natural cartilage. Spryng® assists in promoting a constructive restoration of diseased synovial tissue to improve the biomechanics and mechanical homeostasis of the joint. Furthermore, these particles are designed and engineered to provide a bio-integrative scaffold in the affected joint, promoting restoration of proper joint mechanics.

 

Osteoarthritis, a common inflammatory joint disease in both dogs and horses, is a chronic, progressive, degenerative joint disease that is caused by a loss of synovial fluid and/or the deterioration of joint cartilage. Osteoarthritis affects approximately 14 million dogs and 1 million horses in the $11 billion companion animal veterinary care and product sales market.

 

27

 

 

Despite the market size, veterinary clinics and hospitals have very few treatments and/or drugs for use in treating osteoarthritis in dogs, horses, and other pets. As there is no cure for osteoarthritis, current solutions treat symptoms, but do not manage the cause. The current treatment for osteoarthritis in dogs generally consists of the use of nonsteroidal anti-inflammatory drugs (or “NSAIDs”) which are approved to alleviate pain and inflammation but present the potential for side effects relating to gastrointestinal, kidney, and liver damage and do not halt or slow joint degeneration. The Company offers an alternative to traditional treatments that only address the symptoms of the affliction. our Spryng® product addresses the affliction, loss of synovial fluid and/or the deterioration of joint cartilage, rather than treating just the symptoms and, to the best of our knowledge, has elicited minimal adverse side effects in dogs and horses. Spryng®-treated dogs and horses have shown an increase in activity even after they no longer are receiving pain medication or other treatments. Other treatments for osteoarthritis include steroid and/or hyaluronic acid injections, which are used for treating pain, inflammation and/or joint lubrication, but can be slow acting and/or short lasting.

 

We believe Spryng® is an optimal solution to safely improve joint function in animals for several reasons:

 

  ● Spryng® addresses the underlying problems which relate to deterioration of cartilage causing bones to contact each other and a lack of synovial fluid. Spryng® provides a biocompatible lubricious cushion to the joint, which establishes a barrier between the bones, thereby protecting the remaining cartilage and bone.
  ● Spryng® is easily administered with the standard intra-articular injection technique. Multiple joints can be treated simultaneously.
  ● Case studies indicate many dogs and horses have long-lasting multi-month improvement in lameness after having been treated with Spryng®
  ● After receiving a Spryng® injection, many canines are able to discontinue the use of NSAID’s, eliminating the risk of negative side effects.
  ● Spryng® is an effective and economical solution for treating osteoarthritis. A single injection of Spryng®  is approximately $600 to $900 per joint and typically lasts for at least 12 months.

 

Historically, drug sales represent up to 30% of revenues at a typical veterinary practice (Veterinary Practice News). Revenues and margins at veterinary practices are being eroded because online, big-box, and traditional pharmacies have recently started filling veterinary prescriptions. Veterinary practices are looking for ways to replace lost prescription revenues with safe and effective products. Spryng® is a veterinarian-administered medical device that should expand practice revenues and margins. We believe that the increased revenues and margins provided by Spryng® will accelerate its adoption rate and propel it forward as the standard of care for canine and equine lameness related to or due to synovial joint issues.

 

We commenced sales of Spryng® in the second quarter of fiscal 2022 and plan to increase our commercialization efforts of Spryng® in the United States through distribution relationships while using sales reps, clinical studies, and market awareness to educate and inform key opinion leaders on the benefits of Spryng®

 

We entered into a Distribution Services Agreement (“Distribution Agreement”) with MWI on June 17, 2022. Pursuant to the Agreement, we appointed MWI to distribute, advertise, promote, market, supply, and sell the Company’s lead product, Spryng® on an exclusive basis for two (2) years within the United States (the “Territory”), transitioning to a non-exclusive basis thereafter; provided however that the Company shall extend the exclusivity for an additional one (1) year if MWI achieves certain performance targets agreed upon by the parties. The Company can continue to sell Spryng® within the Territory to established accounts, which include: (a) customers who have purchased Spryng® from the Company prior to the date of the Agreement, (b) customers who require that they deal directly with the Company, (c) governmental agencies, and (d) customers that order via the internet who are not directly solicited by MWI to purchase Spryng® All customers must be licensed veterinary practices.

 

In December 2023, the Company and MWI agreed to change the Distribution Agreement from an exclusive distribution agreement to a non-exclusive distribution agreement, effective as of January 1, 2024. This is consistent with the Company’s strategy to create multiple sales channels for its products. In February 2025, the non-exclusive distribution agreement with MWI expired.

 

In December 2023, the Company entered into a non-exclusive distribution agreement with Covetrus North America, LLC (“Covetrus Distribution Agreement”), to market, distribute and sell the Company’s products in the United States, including the District of Columbia. The Covetrus Distribution Agreement had an initial term of one year, which was not automatically renewed, and as of February 2025, the distribution agreement with Covetrus North America, LLC expired.

 

28

 

 

In December 2024, we entered into new wholesale distribution partnerships with Vedco Inc. (“Vedco”) and Clipper Distributing, LLC (“Clipper”), both leaders in logistical solutions and supply of products to veterinarians through the channel-of-distribution for veterinarians. Both MWI and Covetrus have the capability to purchase directly from Vedco and/or Clipper.

 

Spryng® is classified as a veterinary medical device under the United States Food and Drug Administration (“FDA”) rules and pre-market approval is not required by the FDA. Spryng® completed a safety and efficacy study in rabbits in 2007. Since that time, more than 2,000 horses and dogs have been treated with Spryng®. We entered into a clinical trial services agreement with Colorado State University on November 5, 2020. This university clinical study was completed in March 2024. Additionally, the Company successfully completed an equine tolerance study in March 2022 and began a two canine clinical study with Ethos Veterinary Health, the first beginning in May of 2022 which was completed in October 2023, and the second began in June of 2023 and was completed in December 2024. We anticipate these and other studies that we plan to initiate will be primarily used to expand our distribution outlets since the large international and national distributors generally require a third-party university study and other third-party studies prior to including a product in their catalog of products.

 

We manufacture our products in an ISO 7 certified clean room manufacturing facility in Minneapolis using our patented and scalable self-assembly production process, which minimizes the infrastructure requirements and manufacturing risks to deliver a consistent, high-quality product while being responsive to volume requirements.

 

We also have a pipeline of therapeutic devices for both veterinary and human clinical applications. Some such devices may be regulated by the FDA or other equivalent regulatory agencies, including but not limited to the Center for Veterinary Medicine (“CVM”). We anticipate growing our product pipeline through the acquisition or in-licensing of additional proprietary products from human medical device companies specifically for use in pets. In addition to commercializing our own products in strategic market sectors and in view of the Company’s vast proprietary product pipeline, the Company may establish strategic out-licensing partnerships to provide secondary revenues.

 

RESULTS OF OPERATIONS

 

The following discussion should be read in conjunction with our 2026 10-K Report and the condensed consolidated financial statements and related notes in Item 1, Financial Statements appearing elsewhere in this Quarterly Report on Form 10-Q (“10-Q Report”). The following discussion may contain forward-looking statements, and our actual results may differ materially from the results suggested by these forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in Part I, Item 1A of our 2026 10-K Report under the heading “Risk Factors,” as updated and supplemented by risks described in other SEC filings. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law.

 

We are a smaller reporting company and have incurred substantial losses in connection with our operations. We will need substantial capital to pursue our current plans to commercialize our initial product, Spryng®.

 

RESULTS OF OPERATIONS

 

  

For the Three Months Ended

September 30,

  

For the Six Months Ended

September 30,

 
   2026   2025   2026   2025 
                 
Revenues  $212,806   $303,284   $550,377   $600,784 
                     
Cost of Sales   16,731    83,226    130,985    194,000 
                     
Operating Expenses   2,127,080    2,285,425    3,959,246    4,316,467 
                     
Other (Expense) Income   (15,526)   (179,183)   (20,565)   (645,904)
                     
Net Loss  $(1,946,531)  $(2,244,550)  $(3,560,419)  $(4,555,587)
                     
Net loss per share - basic and diluted  $(0.05)  $(0.09)  $(0.10)  $(0.18)

 

29

 

 

For The Three Months Ended September 30, 2026, Compared to The Three Months Ended September 30, 2025

 

Total Revenues. Revenues were $212,806 and $303,284 for the three months ended September 30, 2026 and 2025, respectively. Revenues in the three months ended September 30, 2026, consist of sales of our Spryng® products of $149,573; PrecisePRP™ products of $6,941; and $57,264 from the reversal of a rebate liability under a distribution agreement that expired in February 2025, offset by sales discounts of ($973). The liability should have been reversed in fiscal 2025 and was recorded in the current quarter as an out-of-period adjustment, which management concluded was not material to any period. Excluding this adjustment, revenues decreased 49% for the three months ended September 30, 2026 compared to the three months ended September 30, 2025. Revenues in the three months ended September 30, 2025, consisted of sales of our Spryng® products of $186,902 and PrecisePRP™ products of $116,382. The decrease in our revenues in the three months ended September 30, 2026, compared to the three months ended September 30, 2025, is due to decreased PrecisePRP™ product sales as a result of the termination of our VetStem licensing agreement on July 24, 2026. Further, our Spryng product revenues declined from the same three month period in 2025, as in 2025, we had a new distributor who had a larger opening order. Also, our rebate liability reversal will be non-recurring as this was a one-time event.

 

Cost of Sales. Cost of sales were $16,731 and $83,226 for the three months ended September 30, 2026 and 2025, respectively. Cost of sales includes product costs related to the sale of our Spryng® products and labor and overhead costs and product costs related to the sale of PrecisePRP™ products. The decrease in our cost of sales in the three months ended September 30, 2026, compared to the three months ended September 30, 2025, is due to a decreased sales of PrecisePRP™ products.

 

Operating Expenses. Operating expenses were $2,127,080 and $2,285,425 for the three months ended September 30, 2026 and 2025, respectively. The decrease is primarily due to decreased general and administrative (“G&A”) expenses due to decreased employee stock compensation.

 

General and administrative (“G&A”) expenses were $921,321 and $1,236,730 for the three months ended September 30, 2026 and 2025, respectively. General and administrative expenses include compensation and benefits, contracted services, legal and consulting fees, and stock compensation expenses. The reduction in general and administrative expenses was due to reduced consulting fees and reduced employee stock compensation expenses.

 

Sales and marketing expenses were $645,933 and $787,262 for the three months ended September 30, 2026, and 2025, respectively. Sales and marketing expenses include compensation, consulting, and tradeshows to support the launch of our Spryng® product. The decrease in sales and marketing expenses was due to reduced marketing expenses and reduced sales expense due to employing less salespeople during the period.

 

Loss on termination of licensing agreement was a one-time event on July 24, 2026 resulting in a non-recurring expense of $237,530 and $0 for the three months ended September 30, 2026, and 2025, respectively.

 

Research and development (“R&D”) expenses were $322,296 and $261,433 for the three months ended September 30, 2026 and 2025, respectively. The increase was primarily related to increased clinical studies expenses.

 

Operating Loss. As a result of the foregoing, our operating loss was $1,931,005 and $2,065,367 for the three months ended September 30, 2026 and 2025, respectively. The decrease was related to decreased expenses in general and administrative expenses.

 

Other Income (Expense). Other expense was $15,526 for the three months ended September 30, 2026, compared to other expense of $179,183 for the three months ended September 30, 2025. The decrease in other expense was due to a decrease in interest expense on convertible and nonconvertible notes and amortization expense of debt discount.

 

Net Loss. Our net loss for the three months ended September 30, 2026, was $1,946,531 or ($0.05) per share as compared to a net loss of $2,244,550 or ($0.09) per share for the three months ended September 30, 2025. The decrease was primarily related to interest expense and decreased employee stock compensation expenses. The weighted average number of shares outstanding was 38,023,703 compared to 27,579,136 for the three months ended September 30, 2026 and 2025, respectively.

 

For The Six Months Ended September 30, 2026, Compared to The Six Months Ended September 30, 2025

 

Total Revenues. Revenues were $550,377 and $600,784 for the six months ended September 30, 2026 and 2025, respectively. Revenues for the six months ended September 30, 2026, consist of sales of our Spryng® products of $358,393; PrecisePRP™ products of $136,017; and $57,264 from the reversal of a rebate liability under a distribution agreement that expired in February 2025, offset by sales discounts of ($1,297). The liability should have been reversed in fiscal 2025 and was recorded in the current quarter as an out-of-period adjustment, which management concluded was not material to any period. Excluding this adjustment, revenues decreased 18% for the six months ended September 30, 2026 compared to the six months ended September 30, 2025. Revenues in the six months ended September 30, 2025, consisted of sales of our Spryng® products of $335,145 and PrecisePRP™ products of $265,639. The decrease in our revenues in the six months ended September 30, 2026, compared to the six months ended September 30, 2025, is due to sales of PrecisePRP™ products, pursuant to the termination of our licensing agreement with VetStem.

 

Cost of Sales. Cost of sales were $130,985 and $194,000 for the six months ended September 30, 2026 and 2025 respectively. Cost of sales includes product costs and labor and overhead related to the sale of our Spryng® products and product costs related to the sale of PrecisePRP™ products. The decrease in our cost of sales for the six months ended September 30, 2026, compared to the six months ended September 30, 2025, is due to decreased sales of PrecisePRP™ products.

 

Operating Expenses. Operating expenses were $3,959,246 and $4,316,467 for the six months ended September 30, 2026 and 2025, respectively. The decrease is primarily due to decreased general and administrative (“G&A”) expenses and research and development (“R&D”) expenses.

 

General and administrative (“G&A”) expenses were $1,888,764 and $2,305,547 for the six months ended September 30, 2026 and 2025, respectively. General and administrative expenses include compensation and benefits, contracted services, legal and consulting fees, and stock compensation expenses. The reduction in general and administrative expenses was due to reduced consulting fees and reduced employee stock compensation.

 

Sales and marketing expenses were $1,277,238 and $1,408,974 for the six months ended September 30, 2026 and 2025, respectively. Sales and marketing expenses reduction was due to having less salespeople and attending less trade shows during the six-month period.

 

Loss on termination of licensing agreement was a one-time event on July 24, 2026 resulting in a non-recurring expense of $237,530 and $0 for the six months ended September 30, 2026, and 2025, respectively.

 

Research and development (“R&D”) expenses were $555,714 and $601,946 for the six months ended September 30, 2026 and 2025, respectively. Research and development expenses include compensation, consulting, and clinical study costs. The reduction in research and development expenses was due to spending less on new product development expense during the six-month period.

 

Operating Loss. As a result of the foregoing, our operating loss was $3,539,854 and $3,909,683 for the six months ended September 30, 2026 and 2025, respectively. The decrease was related to decreased expenses in general and administrative (“G&A”) and research and development (“R&D”).

 

Other Income (Expense). Other expense was $20,565 and $645,904 for the six months ended September 30, 2026 and 2025, respectively. Other expense in 2026 consisted of interest expense. Other expense in 2025 consisted of unrealized loss on change in derivative liabilities, loss on lease termination, amortization of debt discount, and interest expense.

 

Net Loss. Our net loss for the six months ended September 30, 2026 was $3,560,419 or ($0.10) per share as compared to a net loss of $4,555,587 or ($0.18) per share for the six months ended September 30, 2025. The decrease was related to decreased employee stock compensation expense, decrease in the unrealized loss on change in derivative liabilities, decrease in loss on lease termination, decrease in amortization of debt discount and interest expense. The weighted average number of shares outstanding was 37,542,128 compared to 25,949,915 for the six months ended September 30, 2026 and 2025, respectively.

 

30

 

 

LIQUIDITY AND CAPITAL RESOURCES

 

As of September 30, 2026, our current assets were $697,545, including $16,287 in cash and cash equivalents. In comparison, our current liabilities as of that date were $2,257,362 including $905,066 of accounts payable and accrued expenses. Our working capital deficit as of September 30, 2026 was $1,559,817.

 

The Company has continued to realize losses from operations. As a result, we do not believe we will have sufficient cash to meet our anticipated operating costs and capital expenditure requirements for at least the next twelve months. We expect to fund our cash needs in part with proceeds of a private offering of up to $2 million initiated in late October 2026. As of the date of this Form 10-Q filing, no subscriptions have been signed and no proceeds have been received by the Company.

 

On October 6, 2026, OTC Markets downgraded our listing from OTCQX (Best Market) to OTCQB (Venture Market), due to OTCQX maintenance listing requirements whereby we have not met the $2 million net tangible assets threshold under Rule 3a51-1 of the Exchange Act. This downgrade could affect investor perception, reduce institutional liquidity and access, and lower trading volumes.

 

Also, the investor affiliate/related party who subscribed to a purchase option with a remaining subscription of $1.35 million is not obligated to exercise, as the purchase option was extended to December 15, 2026. As of the date of this Form 10-Q filing, no proceeds have been received on the remaining subscription of $1.35 million from this affiliate investor.

 

We are also working with a few investment banks for an additional capital raise. Furthermore, we are negotiating with a private investor for up to $10 million investment in our new human subsidiary, Somatrix Technologies, Inc.

 

The additional capital in the future will support our efforts to continue to commercialize Spryng® and our ongoing operations. We expect to continue to raise additional capital through the sale of our securities from time to time for the foreseeable future to fund our business expansion. Our ability to obtain such additional capital will likely be subject to various factors, including our overall business performance and market conditions. There can be no guarantee that the Company will be successful in its ability to raise additional capital to fund its business plan.

 

Net Cash Used in Operating Activities – We used $1,912,820 of net cash in operating activities for the six months ended September 30, 2026. This cash used in operating activities was primarily attributable to our net loss of $3,560,419.

 

Net Cash Used in Investing Activities – During the six months ended September 30, 2026, net cash used in investing activities was $26,675.

 

Net Cash Provided by Financing Activities – During the six months ended September 30, 2026, net cash provided by financing activities of $1,755,000 consisted of proceeds of common stock receivable of $600,000, proceeds from issuance of common stock of $200,000 and proceeds of $955,000 from the issuance of notes payable.

 

MATERIAL COMMITMENTS

 

Notes Payable

 

As of September 30, 2026, we are obligated on non-convertible notes and accrued interest of $1,296,850.

 

VetStem, Inc. Termination of Licensing Agreement

 

On July 24, 2026, we signed a licensing termination agreement with VetStem, Inc. The termination agreement resulted in a settlement payment to VetStem, Inc. of $75,000 for the return of all PrecisePRP™ products (with a gross value of $359,981, and an inventory allowance of $239,935) resulting in an inventory write-down of $120,046. The license agreement was also written off, with a net carrying value of $325,000 (cost of $2,000,000, less accumulated amortization of $550,000, accumulated impairment of $1,000,000 and the $125,000 contract payable reduction). In addition, outstanding accounts payable of $144,866, accrued royalties of $12,650, and a milestone contract payment of $125,000, totaling $282,516, were also forgiven by VetStem Inc. This resulted in a total net loss of $237,530 recorded as a loss on VetStem licensing agreement for the three and six months ended September 30, 2026.

 

OFF-BALANCE SHEET ARRANGEMENTS

 

As of September 30, 2026, and as of the date of this Quarterly Report, we do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

 

GOING CONCERN

 

The financial statements have been prepared assuming that we will continue as a going concern, which contemplates that we will realize our assets and satisfy our liabilities and commitments in the ordinary course of business. Our working capital deficit at September 30, 2026, was $1,559,817.

 

The Company incurred a net loss of $3,560,419 for the six months ended September 30, 2026, had net cash used in operating activities of $1,912,820 for the same period, and has an accumulated deficit of $105,122,925 on September 30, 2026. The Company had a working capital deficit of $1,559,817; a stockholders’ deficit of ($159,093); cash on hand at September 30, 2026 of $16,287 and $1,275,000 of non-convertible notes, in addition to $360,000 of new notes issued in October and November 2026, all maturing within twelve months. Also, the Company initiated a $2,000,000 private equity offering in late October, to raise new capital for the company. As of the date of this Form 10-Q filing, no subscription agreements have been signed, and no proceeds have been received by the Company.

 

These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these consolidated financial statements are issued.

 

Management’s plans to address these conditions include continuing efforts to improve operating results, reduce operating costs, increase revenues, and obtain additional capital through debt and/or equity financing arrangements. The Company has historically relied on external financing to fund its operations and expects to continue to seek additional financing as needed.

 

There can be no assurance that the Company will be successful in achieving profitable operations, securing additional financing on acceptable terms, or successfully implementing its business plan. Accordingly, management has concluded that substantial doubt about the Company’s ability to continue as a going concern is not alleviated.

 

CRITICAL ACCOUNTING POLICIES

 

We prepare our consolidated financial statements in accordance with generally accepted accounting standards in the United States of America. Our significant accounting policies are described in Note 1 to our condensed consolidated financial statements attached hereto. We believe our significant accounting policies, as described in Note 1 to the condensed consolidated financial statements, involve the most significant judgments and estimates used in the preparation of the condensed consolidated financial statements.

 

RECENTLY ISSUED ACCOUNTING STANDARDS

 

The Company has reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management.

 

31

 

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. This ASU is effective for public entities with fiscal years beginning after December 15, 2024. The Company adopted this guidance for the year ended March 31, 2026 and applied the guidance on a retrospective basis. The adoption did not have a material impact on the consolidated financial statements.

 

The Company has reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effective dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles, other than ASU 2023-09, Income Taxes (Topic 740) discussed above, and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to formal review of the Company’s financial management.

 

All other newly issued but not yet effective accounting pronouncements have been deemed either immaterial or not applicable.

 

ITEM 3. QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

 

ITEM 4. CONTROLS AND PROCEDURES

 

DISCLOSURE CONTROLS AND PROCEDURES

 

During the quarter, the Company’s management performed an evaluation, under the supervision and with the participation of the Company’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as that term is defined in Rules 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The term “disclosure controls and procedures” means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Based on that evaluation our CEO and CFO concluded that as of September 30, 2026, our disclosure controls and procedures were not effective due to previously disclosed material weaknesses in internal control over financial reporting. These material weaknesses relate to the design and operation of controls over the accounting for modifications of convertible notes, measurement of beneficial conversion features, warrant debt discounts, and derivative liabilities.

 

Remediation

 

Management is in the process of implementing measures designed to ensure that the control deficiencies contributing to the material weaknesses are remediated, such that these controls are designed, implemented, and operating effectively. The remediation actions include: (i) tightening the ICFR controls moving forward, (ii) improving existing training program associated with our accounting for convertible notes, warrant discounts and derivative liabilities, and (iii) hiring additional accounting personnel, including adding a senior accounting position with derivative accounting and warrant discount experience. We believe that these actions will remediate the material weaknesses with our internal control over financial reporting. Management began implementing these remedial steps during the quarter ended September 30, 2026, as described under Changes in Internal Control Over Financial Reporting below, and plans to complete them during the remainder of the fiscal year. The material weaknesses will not be considered remediated, however, until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.

 

Changes in Internal Control Over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting as defined in Rule 13a-15(f) and 15d-15(f) promulgated under the Securities Exchange Act of 1934. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles (GAAP) and includes those policies and procedures that:

 

  ● Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;
  ● Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and our directors; and
  ● Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, our internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems if determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Our management assessed the effectiveness of our internal control over financial reporting as of September 30, 2026. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control — Integrated Framework (revised 2013). This assessment included an evaluation of the design and procedures of our control over financial reporting.

 

Management has concluded that as of September 30, 2026, our internal control over financial reporting was not effective.

 

During the quarter ended September 30, 2026, management has implemented the following internal controls over financial reporting with new structured procedures in our accounting department to ensure the accuracy, integrity and compliance of our financial statements. New procedures include: i) new policies on review of journal entry approval with CFO review with new thresholds; ii) hiring outside technical accounting assistance regarding compliance with ASC (Accounting Standards Codification) accounting practices, in accordance with the U.S. Generally Accepted Accounting Principles (GAAP), as maintained by the Financial Accounting Standards Board (FASB); and iii) new procedures in recording proper period revenue recognition controls.

 

Except as described above, there were no changes in our internal control over financial reporting during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

32

 

 

PART II. OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business. In June 2026, a former employee filed a whistleblower retaliation complaint with the Occupational Safety and Health Administration (OSHA) under Sarbanes-Oxley Act (SOX), 18 U.S.C. § 1514A. The claimant alleges they were wrongfully terminated after reporting alleged governance and honesty in shareholder relations.

 

The Company is cooperating with OSHA’s ongoing investigation, denies all allegations and intends to vigorously defend against these allegations. At this preliminary stage, the outcome is uncertain. Although the Company cannot predict the ultimate outcome of this matter, based on currently available information, management cannot estimate the possible loss or range of loss because such amount cannot be reasonably estimated. Management does not believe that the ultimate resolution of this matter will have a material adverse effect on the Company’s consolidated financial position, results of operations, or cash flows.

 

ITEM 1A. RISK FACTORS

 

In addition to the other information set forth in this Quarterly Report, you should carefully consider the factors discussed in Part I, Item 1A Risk Factors in our Annual Report on Form 10-K for our fiscal year ended March 31, 2026. The risks described in our latest Annual Report on Form 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be insignificant also may materially and adversely affect our business, financial condition, or operating results in the future. Also, On October 6, 2026, OTC Markets downgraded our listing from OTCQX (Best Market) to OTCQB (Venture Market), due to OTCQX maintenance listing requirements whereby we have not met the $2 million net tangible assets threshold under Rule 3a51-1 of the Exchange Act. This downgrade could affect investor perception, reduced institutional liquidity and access, and lower trading volumes.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

In April 2026, the Company issued 176,174 shares of common stock for the conversion of dividends declared on Series B preferred stock fair valued at $125,000.

 

In April 2026, the Company issued 62,500 shares of common stock to 5 board members for advisory and consulting services fair valued at $42,000.

 

In April 2026 and June 2026, the Company issued 937,500 shares of common stock in exchange for proceeds of $750,000 as part of a private placement subscription agreement.

 

In April 2026 through June 2026, the Company issued 368,152 shares of common stock to 6 employees for performance awards fair valued at $288,225.

 

In June 2026, the Company issued 200,000 shares to a service provider for consulting services valued at market on the date of grant of $160,000.

 

In July 2026 through September 2026, the Company issued 242,157 shares of common stock to 6 employees for performance awards fair valued at $190,050.

 

In July 2026, the Company issued 156,250 shares of common stock for the conversion of dividends declared on Series B preferred stock fair valued at $125,000.

 

In July 2026, the Company issued 50,000 shares of common stock to 5 board members for advisory and consulting services fair valued at $42,000.

 

In September 2026, the Company issued 12,628 shares of common stock to a board member for the conversion of accrued board compensation fair valued at $8,587.

 

In September 2026, the Company issued 11,865 shares of common stock to a board member for the conversion of 35,954 stock options fair valued at $8,068.

 

In September 2026, the Company issued 62,500 shares of common stock in connection with the sale of stock at a price of $0.80 per share in exchange for proceeds of $50,000.

 

All of the transactions described above, including the issuance of 212,500 warrants in the six months ending September 30, 2026 are also unregistered securities and were exempt from registration in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, as a transaction by an issuer not involving a public offering. The consultants in these transactions represented their intention to acquire these securities for investment only and not with a view to offer or sell, in connection with any distribution of the securities, and appropriate legends were affixed to the share certificates and instruments issued in such transactions.

 

33

 

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not required.

 

ITEM 5. OTHER INFORMATION

 

No director/officer adopted, modified or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the quarter.

 

ITEM 6. EXHIBITS

 

The following exhibits are filed as part of this Quarterly Report.

 

Exhibit No.   Description
     
10.1   Termination and Settlement Agreement, dated July 24, 2026, by and between PetVivo Holdings, Inc. and VetStem, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on July 29, 2026).
     
10.2   Subscription Agreement with John Lai, CEO, dated September 6, 2026.
     
10.3   Subscription Agreement with Garry Lowenthal, CFO, dated September 6, 2026.
     
10.4   Form of Promissory Note to related parties
     
31.1**   Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
31.2**   Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
32.1**   Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
32.2**   Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101.INS   Inline XBRL Instance Document
     
101.SCH   Inline XBRL Taxonomy Extension Schema
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase
     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase
     
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

** Filed herewith

 

34

 

 

PETVIVO HOLDINGS, INC.

 

SIGNATURES

 

Pursuant to the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

November 16, 2026 By: /s/ John Lai
    John Lai
  Its: CEO, President, and Director
    (Principal Executive Officer)

 

November 16, 2026 By: /s/ Garry Lowenthal
    Garry Lowenthal
  Its: Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

35

Keep reading